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ABSTRACT 
Background: Despite the prevalent nature of adverse drug reactions (ADRs) and its negative 
impact on treatment outcomes in patients on antiretroviral therapy (ART), the impact of ADRs 
on HIV treatment outcomes - including virologic failure, at Jos University Teaching Hospital 
HIV clinic have not been fully explored. Identifying ADRs and understanding their risk factors 
could aid early management and ultimately improve treatment outcomes. 
Aim: The aim of the research was to investigate the frequency, types, and risk factors of clinical 
ADRs to antiretroviral medicines (ARVs) and assess if ADRs increased the risk of virologic 
failure in patients on ART. 
Methodology: A retrospective cohort study design was utilized. Data of HIV-1 infected patients, 
≥18 years of age, treatment naïve at enrolment and receiving first-line ART at Jos University 
Teaching Hospital HIV clinic between June 2004 and February 2012 were evaluated. The 
incidence and spectrum of ART-associated ADRs were described, and factors associated with 
ADRs were assessed by Chi-square analyses.  A multivariate logistic regression model was fitted 
to identify independent predictors of ADRs. The association between ADRs and virological 
failure was assessed by multivariate logistic regression. All statistical tests were two-tailed and a 
p-value <0.05 was considered statistically significant. Stata (version 13) was used for the 
statistical analyses. 
Results: A total of 12,115 patients with a mean age of 35.8 ± 9.1 years, and predominantly 
females (67%) were included in the analyses. The majority (76%) of the study participants 
initiated nevirapine-based ART, while zidovudine was the most frequently used nucleoside 
reverse transcriptase inhibitor (50.2%). In all, 918 incident ADRs were documented during a 
median (interquartile range) of 4 (1-7) years follow-up period; 45,034 person-years (py) of 
observation. The incident rate of ADRs was 20 (95% CI: 19 – 22) per 1000 py and was highest 
during the first year of ART (41 per 1000 py versus 14 per 1000 py, for ≤1 year and >1 of ART; 
crude incident rate ratio, 2.87 (95% CI: 2.53-3.24)). Compared to other grades of ADRs, the 
prevalence of severe ADRs was highest (4.5%), while 2.6% ADRs were moderate, and 0.8% 
were mild. The most common types of ADRs were lipodystrophy (2.6%) attributable mostly to 
the use of stavudine, and anaemia (1.9%) mainly due to zidovudine use. Others included skin 
rash and itching (0.7%), peripheral neuropathy (0.5%), and nightmares and insomnia (0.4%). The 
likelihood of ADRs increased by a factor of 2% for every one-year increment in age (OR, 1.02; 
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95% CI: 1.01-1.03; p<0.001). Among the nucleoside reverse transcriptase inhibitors, compared 
to tenofovir, ADRs were more likely with the following ARVs: abacavir (OR, 2.11; 95% CI: 
1.23-3.61; p =0.007), zidovudine (OR, 2.22; 95% CI: 1.74-2.84; p <0.001), stavudine (OR, 15.9; 
95% CI: 11.07-21.11; p <0.001), and didanosine (OR, 2.13; 95% CI: 1.25-3.63: p <0.006). The 
prevalence of virologic failure was 36% at 24 weeks of ART, 29% at 48 weeks, and 34% at 72 
weeks of ART. Antiretroviral therapy-related anaemia increased the odds of virologic failure at 
72 weeks by 74% (OR, 1.74; 95% CI: 1.2 - 2.51; p <0.001); adjusting for age, sex, baseline 
disease stage, pre-treatment CD4+ cell count, antiretroviral regimen, and year of ART initiation.   
 
Conclusion and Recommendations: The incidence of reported ADRs in the studied population 
was low and occurred more frequently in the first year of therapy. The risk of ART-related 
ADRs increased with age. Of the ADRs experienced by patients in the studied population, 
anaemia significantly increased the risk of late virologic failure. Routine monitoring of 
haemoglobin levels and prompt management of anaemia in all patients on ART is recommended 
as a strategy to improve virologic success rates. In addition, close follow-up of patients, 
throughout the duration of ART, is recommended to track both early and late onset ADRs and to 
manage them promptly. 
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DEFINITIONS OF KEY CONCEPTS AND TERMS 
Except indicated otherwise, the terms are from Edwards and Aronsom (2000), WHO (2006), 
(AIDSinfo, 2015), and WHO (2012). 
Terms related to negative effects of drugs 
Adverse [drug] reaction (ADR): An adverse [drug] reaction (ADR) is an adverse response 
to a medicine, which is noxious and unintended and which occurs at doses normally 
recommended for use in humans.  
Adverse event or experience: An adverse event or experience is any untoward medical 
occurrence that may present during treatment with a medicine but which does not 
necessarily have a causal relationship to the treatment.  
Avoidable (preventable) adverse reactions: Avoidable adverse reactions are those that can 
be predicted and that can, therefore, be prevented from happening.  
Classification and coding of ADRs  
Adverse reactions may be described and coded in terms of the body’s systems and organs by 
using the WHO Adverse Reaction Terminology (WHO-ART) or the Medical Dictionary for 
Drug Regulatory Activities (MedDRA). 
Long-term ADR: A long-term ADR occurs after the passage of a reasonably long period of 
time (months or years) after the administration of a medicine.  
Side effect: A side effect is an unintended effect of a pharmaceutical product occurring at 
doses normally used in humans, which is related to the pharmacological properties of the 
drug.  
Serious adverse events are those that:  
 are life-threatening  
 cause or prolong hospital admission  
 cause persistent incapacity or disability  
 are sometimes caused by misuse or dependence on a particular drug  
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Severity of ADR: The severity of an adverse reaction denotes the intensity of the effect, 
which may be mild, moderate or severe.  
Short-term ADR: A short-term ADR occurs within a reasonably short interval after 
administration (such as minutes or days after the administration of a medicine).  
The seriousness of ADRs: The seriousness of adverse drug reactions is based on the 
seriousness of the outcome or harm caused to the patient.  
Type A and B adverse effects  
Type A adverse effects: Type A adverse effects are those that are caused by the heightened 
(exaggerated) pharmacological effects of a drug. They are fairly common, predictable, dose-
related, and are avoided by using doses that are better tolerated by an individual patient.  
Type B adverse effects: Type B adverse effects are generally rare, unpredictable and may be 
serious. They may be immunological or non-immunological and occur in patients with often 
unknown predisposing conditions.  
Rare adverse event: A rare adverse event is an event with a probability frequency of 
between 1 in 10,000 and 1 in 1,000.  
Spontaneous reporting system: A spontaneous reporting system is a system whereby case 
reports of suspected adverse drug events are voluntarily submitted by health professionals, 
patients and pharmaceutical manufacturers to the national drug regulatory authority. 
Unexpected adverse reaction: An unexpected adverse reaction is an adverse reaction, the 
nature or severity of which is not consistent with domestic labelling or marketing 
authorization, and which is not expected from the characteristics of the drug. 
Terms related to antiretroviral therapy 
First-line antiretroviral therapy: A treatment that is accepted as best for the initial 
treatment of a condition or disease. The recommended first-line HIV treatment regimens 
include antiretroviral (ARV) drugs that are safe, effective, and convenient for most people 
with HIV who have never taken ARVs before. 
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Regimen backbone: The two nucleoside reverse transcriptase inhibitors (NRTIs) upon 
which an initial HIV regimen is built. To complete the HIV regimen, the two NRTIs are 
combined with a third antiretroviral HIV drug from either the non-nucleoside reverse 
transcriptase inhibitor (NNRTI), protease inhibitor (PI), or integrase strand transfer inhibitor 
(INSTI) drug class. 
Salvage therapy: therapy given when the standard treatment for a disease or condition is no 
longer effective and when treatment options are limited. People with HIV who have 
experienced toxicity and/or developed resistance to many HIV drugs receive salvage 
therapy. 
Terms related to outcome of antiretroviral therapy 
Clinical failure: new or recurrent clinical event indicating severe immunodeficiency (WHO 
clinical stage 4 conditions) after 6 months of effective treatment (World Health 
Organization (WHO), 2016a). 
Immunological failure: CD4 count at or below 250 cells/mm3 following clinical failure or 
persistent CD4 levels below 100 cells/mm3(World Health Organization (WHO), 2016a). 
Viral load (VL): the amount of HIV in a sample of blood. Viral load (VL) is reported as the 
number of HIV RNA copies per millilitre of blood. An important goal of antiretroviral 
therapy (ART) is to suppress a person’s VL to an undetectable level—a level too low for the 
virus to be detected by a VL test. 
Viral suppression: when antiretroviral therapy (ART) reduces a person’s viral load (HIV 
RNA) to an undetectable level. 
Virologic failure: viral load above 1000 copies/mL based on two consecutive viral load 
measurements in 3 months; with adherence support following the first viral load test, after at 
least 6 months of antiretroviral therapy (World Health Organization (WHO), 2016a) 
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
1.1.1 Global and national epidemiology of HIV 
Since 1981 when acquired immunodeficiency syndrome (AIDS) was first described (Centers for 
Disease Control (CDC), 1981) and the discovery of the Human Immunodeficiency Virus (HIV) 
(Barré-Sinoussi et al., 1983), more than 70 million people have been infected with the HIV virus 
and about 35 million people have died of HIV (UNAIDS, 2016). Despite the concerted global 
effort to combat the HIV epidemic, the 2016 report of the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) shows that HIV is still a major public health problem affecting an 
estimated 36.7 million people globally at the end of 2015 (UNAIDS, 2016). The report indicated 
that there were about 2.1 million new HIV infections and 1.1 million AIDS-related deaths 
globally by the end of 2015. Sub-Saharan Africa is the region worst affected by the HIV 
epidemic, with an estimated 25.5 million HIV-infected persons living in the region (69% of 
global HIV cases) (UNAIDS, 2016). 
 
Available data indicate that Nigeria bears the second highest burden of HIV-infected persons 
globally, after South Africa, with an estimated 3.5 million people living with the virus, which is 
about 10% of all persons living with HIV globally in 2013 (UNAIDS, 2014). Although HIV 
prevalence in Nigeria is relatively stable at 3.4% (National Agency for the Control of AIDS 
(NACA), 2015), there is wide variability in the prevalence across states and zones in Nigeria as 
shown in Figure 1.1 below; ranging from as low as 0.2% in a South Western State to as high as 
15.1% in a South-South State (Federal Ministry of Health (Nigeria), 2013). Generally, the 2012 
Nigerian National HIV/AIDS and Reproductive Health Survey (NARHS) report revealed that the 
HIV prevalence by zone was highest in the South-South geopolitical zone, followed by North 
Central zone, and lowest in the South East zone. Across demographic groups, HIV prevalence 
was highest among those aged 35 to 39 (4.4%), and lowest among the 15-19 age group (2.9%), 
while the prevalence for males aged 35 to 39 years was highest at 5.3%, and women aged 30 to 
34 years was 4.2% (Federal Ministry of Health (Nigeria), 2013). 
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Figure 1.1: Distribution of HIV prevalence by states in Nigeria, 2012 
Source: (National Agency for the Control of AIDS (NACA), 2015, p. 40) 
 
Key drivers of the HIV epidemic in Nigeria include low personal risk perception, multiple 
concurrent sexual partnerships, transactional and intergenerational sex, ineffective and inefficient 
services for sexually transmitted infections (STIs), and inadequate access to quality healthcare 
services (National Agency for the Control of AIDS (NACA), 2015). 
 
1.1.2 Global and national response to HIV/AIDS epidemic 
Considerable progress has been made in combating the HIV epidemic globally. As depicted in 
Figure 1.2, the 2016 UNAID estimates show a reversal in the HIV epidemic curve in the number 
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of new infections (UNAIDS, 2016). According to the UNAIDS, 2016 report, since the 2000s, the 
number of new infections declined steadily by about 6%, with the greatest decrease in HIV 
incidence observed among children, which has been reduced by 50% since 2010.  
 
 
Figure 1.2: Trend in the number of persons newly infected with HIV from 1990 to 2015 
Source: UNAIDS estimates 2016 
 
The achievement of maximum effect at the population level in the reduction of HIV transmission 
in specific settings has been possible through a combination of prevention strategies involving 
the application of several evidence-based interventions such as a combination of biomedical, 
behavioural, and structural strategies in a highly focused public health approach (UNAIDS, 
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2010). The UNAIDS Prevention Reference Group in December 2009 agreed on the operational 
definition of combination prevention programmes as: 
... rights-based, evidence-informed, and community-owned programmes that use 
a mix of biomedical, behavioural, and structural interventions, prioritized to meet the 
current HIV prevention needs of particular individuals and communities, so as to have 
the greatest sustained impact on reducing new infections. (UNAIDS, 2010, p. 8) 
 
According to the 2009 UNAIDS prevention reference group report, well-designed combination 
prevention programmes should be carefully tailored to national and local needs and conditions. 
Importantly, resources should be focused on a mix of programmatic and policy actions required 
to address both immediate risks and underlying vulnerability. In addition, they should be 
thoughtfully planned and managed to operate synergistically and consistently at multiple levels 
such as individual, relationship, community, and society levels over an adequate period of time. 
Furthermore, such programmes should mobilize the community, private sector, government and 
global resources in a collective undertaking, as well as require and benefit from enhanced 
partnership and coordination. Mechanisms for learning, capacity building and flexibility to 
permit continual improvement and adaptation to the changing environment are essential 
components of combination prevention programmes. (UNAIDS, 2010) 
 
Obviously, combination prevention programmes are working; reflected in the declining new HIV 
infections rates (UNAIDS, 2016). It is projected that putting combination prevention 
programmes into practice will help ensure that HIV responses outpace the epidemic in every 
country, and will move the world closer to the UNAIDS’ global vision to reduce new HIV 
infections to fewer than 500 000 globally by 2020 (United Nations, 2016). 
 
1.2 The use of antiretroviral therapy to combat HIV epidemic 
Among the strategies that have been deployed to combat the HIV epidemic, the introduction of 
combination antiretroviral therapy represents one of the most significant interventions that 
changed the landscape of HIV-related mortality (Montaner et al., 1998). Antiretroviral therapy 
substantially modified the natural history of HIV infection and changed it from an end of life 
event to a manageable chronic condition (Deeks, Lewin, & Havlir, 2013). In both high and low-
income countries combination antiretroviral therapy has resulted in improved health, 
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prolongation of life and a significant reduction in the risk of HIV transmission (Deeks et al., 
2013). The life expectancy of HIV-infected persons who are optimally treated is now measured 
in decades and may approach that observed in uninfected population (Johnson et al., 2013). 
 
The global gains attributable to ART has been largely due to improved access to life-saving ART 
(UNAIDS, 2016). The UNAIDS 2016 global HIV/AIDS update indicates that access to ART has 
been on a fast-track trajectory with a steep rise in the number of people accessing life-saving 
antiretroviral therapy increased from below 5 million in 2000 to about 17million as of December 
2015. As shown in Figure 1.3 below, after a peak in 2005, there has been a consistent decline in 
AIDS-related deaths corresponding to increased global access to ART. Available data suggest 
that the gains in treatment contributed significantly to about 26% decline in AIDS-related deaths 
globally since 2010, from an estimated 1.5 million in 2010 to 1.1 million in 2015 (UNAIDS, 
2016). It has been suggested that with Advances in treatment and prevention, it is projected that 
expanded access to treatment in some settings could eventually lead to the elimination of HIV 
(Granich et al., 2015).  
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Figure 1.3: Antiretroviral therapy coverage and number of AIDS-related deaths, global, 
2000–2015 
Source: GARPR 2016; UNAIDS 2016 estimate: p5 
 
Nigeria is not left out in the global response to HIV. The Nigerian National Agency for the 
Control of AIDS (NACA) 2015 estimates show that new infections declined by 24% within a 
decade from an estimated 316,733 in 2003 to 239,155 in 2013 and AIDS-related deaths declined 
by 17% from 210,031 deaths in 2013 to 174,253 in 2014 (National Agency for the Control of 
AIDS (NACA), 2015). According to the NACA, 2015 report, Nigeria has witnessed an upsurge 
in the number of HIV-infected persons accessing life-saving ART since 2002. Coverage of ART 
services increased from 25 health facilities in the year 2002 to 820 in 2013, and from 2009 to 
2014, the number of persons receiving ART more than doubled, from 302,073 to 747 382, 
respectively.  
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1.2.1 Challenges of antiretroviral therapy 
Despite the benefits of ART, it is not without challenges. The initial objectives of the 
introduction of combination antiretroviral therapy was focused on reduction in HIV-1-associated 
mortality and morbidity, but issues such as drug toxicity, resistance and compliance with 
treatment began to emerge as these objectives were being accomplished (Moreno et al., 2010; 
Murphy, Sunpath, Kuritzkes, Venter, & Gandhi, 2007). Adverse drug reactions (ADRs) 
associated with the use of ARVs can rapidly reverse the gains of ART resulting in poorer health 
outcomes (Syed, Sulaiman, Hassali, & Lee, 2015) and increased mortality (Keiser et al., 2007). 
Acute toxicities may lead to dose interruption and discontinuation of therapy. Some studies have 
reported treatment discontinuation rates ranging from 4% to 46% related to neuropsychiatric 
adverse effects of antiretroviral therapy (Bartlett, Chen, & Quinn, 2007; Spire, Carrieri, Garzot, 
L’henaff, & Obadia, 2004). Cumulative toxicities from exposure to antiretroviral drugs for 
decades may result in clinically relevant metabolic disturbances and end-organ damage (Johnson 
et al., 2013). 
 
Antiretroviral therapy associated ADRs increases the cost (Rajesh, Vidyasagar, Muralidhar, & 
Guddattu, 2012) and complexity of managing HIV (Moreno et al., 2010). Direct costs associated 
with ADRs include the cost of treating ADRs, the cost of laboratory investigations, and cost of 
hospitalization stay (Rajesh et al., 2012). Other indirect costs such as disability, work 
productivity losses related to absenteeism and other financial costs are also associated with 
ADRs (Kingston-Riechers, 2011). 
 
1.2.2 Risk factors for adverse drug reactions to antiretroviral therapy in developing 
countries 
The burden of ART-associated ADRs seems to be higher in developing countries compared to 
developed countries (Subbaraman, Chaguturu, Mayer, Flanigan, & Kumarasamy, 2007). 
According to Subberaman et al. (2007), the reason for the disparity between developed and 
developing countries in the burden of ART-related ADRs are: 1) economic constraints which 
limit the repertoire of accessible antiretroviral medications to a  handful older and more toxic 
agents responsible for most of the observed toxicity; 2) prohibitory laboratory monitoring costs 
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may delay the identification of specific toxicities, thereby increasing their severity; 3) high 
prevalence of comorbid conditions like anaemia, malnutrition, tuberculosis, initial presentation 
with advanced immunosuppression (Agaba et al., 2014); 4) concomitant antituberculosis therapy; 
5) the use of herbal medications practices which may influence the incidence of adverse effects; 
and 6) genetic factors - which is an important factor in individual variability to drug response. 
For instance, the incidence of neuropsychiatric ADRs associated with the use of the antiretroviral 
drug efavirenz has been shown to be higher in African compared to Caucasians and Asian 
(Barrett et al., 2002; Pfister et al., 2003). 
 
1.2.3 Prevalence of antiretroviral therapy-related adverse drug reactions 
Adverse drug reactions to ART is common, with reported prevalences ranging from 30% to as 
high as 90% (Lartey et al., 2014; Shet et al., 2014; Subbaraman et al., 2007; Syed et al., 2015).  
Published reports on ART-related ADRs in Nigeria are sparse despite ADRs being common 
among patients on ART. The few available studies in Nigeria estimate the incidence of ART-
related ADRs to be between 4.6% to 10.4% among individuals receiving ART (Abah, Akanbi, et 
al., 2015; Agu et al., 2013; Eluwa, Badru, & Akpoigbe, 2012; Reginald et al., 2012). A high 
prevalence of self-reported ADRs of 73% was documented among patients on ART in a 
Government health facility in Benin City (Balogun & Adeleye, 2014). However, this was a 
cross-sectional study based on patient-reported ADR and is limited in estimating the true 
prevalence of ADR in the setting. Although some studies suggest that acute toxicities associated 
with antiretroviral medicines may lead to dose interruption and discontinuation of therapy 
(Leutscher, Stecher, Storgaard, & Larsen, 2013; Prosperi et al., 2012) which is a risk factor for 
virologic failure (Keiser et al., 2007), reports on the association between ART-associated ADRs 
and virologic failure are sparse.  
 
1.2.4 Global and national prevalence of virologic failure among patients on ART 
The UNAIDS set an international goal for 2020 termed the “90–90–90 target,” which aims to 
increase the number of persons living with HIV (PLWH) who know their serostatus to 90%; 
among those who are diagnosed, to increase the percentage who are prescribed ART to 90%; and 
for 90% of persons on ART to achieve and maintain viral suppression (UNAIDS, 2017). One of 
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the strategies to achieve the viral suppression target, apart from the promotion of adherence, is 
the use of an ART regimen that is well tolerated to promote maximal viral suppression and 
immune reconstitution (Margolis, Heverling, Pham, & Stolbach, 2014). Estimates of viral 
suppression rates after 12 months of antiretroviral therapy in low- and middle-income countries, 
depending on the HIV RNA thresh hold, range from 50% to as high as 90% (McMahon, Elliott, 
Bertagnolio, Kubiak, & Jordan, 2013). Data on HIV treatment cascade in Nigeria are scarce. One 
Nigerian study reported that only 50% of patients on standard care attained undetectable viral 
load of <400 copies per ml after one year of antiretroviral therapy (Taiwo et al., 2010).  The low 
rate of viral suppression among patients on ART in Nigeria is a challenge which requires a 
critical evaluation to understand the factors that underpin poor treatment response to ART. 
 
1.3 Research problem 
In Nigeria and other sub-Saharan Africa countries, where limited medicine options are common 
due to limited resources and providers are constrained to operate with a limited formulary, ART 
regimen durability takes on an important role (Murphy et al., 2007). Failure of first-line ART 
regimens resulting from ADRs creates the need for more expensive and difficult-to-implement 
second-line regimens, often unaffordable in most resource-constrained countries who are largely 
donor dependent for their ART programs (Renaud-Théry et al., 2007). The initial ART regimen 
affords the best opportunity to attain maximal viral suppression. Despite the prevalent nature of 
ADRs among patients on ART and their negative impact on treatment outcomes, the impact of 
ADRs on HIV treatment outcomes including virologic failure among patients accessing ARVs at 
JUTH HIV clinic has not been fully explored. JUTH HIV clinic has one of the largest HIV 
treatment cohorts in Nigeria; with over 20,000 patients enrolled in care (Agaba et al., 2014). 
Previous studies that evaluated treatment outcomes among patients on first-line ART at JUTH 
HIV clinic showed a high level of treatment modification of 83% (Abah, et al., 2015), treatment 
discontinuation of 28% (Agbaji et al., 2015) and virologic failure of 49% (Taiwo et al., 2010) 
among patients receiving standard care. However, the impact of ADRs on virologic failure was 
not evaluated. The research questions for this study are: how common are ADRs due to ART in 
our study setting? What are the common types of ADRs? What are the risk factors for ART-
related ADRs? What is the impact of ADRs on virologic failure? In summary, are patients who 
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experience an ADR at greater risk of virologic failure compared to those who do not experience 
an ADR? 
 
1.4 The setting: a Federal Tertiary Healthcare Facility in Jos,  North-central Nigeria 
The study was carried out at JUTH HIV clinic; a Federal Tertiary Healthcare Facility located in 
the cosmopolitan city of Jos in North-central Nigeria. Jos University Teaching Hospital HIV 
clinic is an outpatient specialist clinic and is one of the largest HIV treatment centres providing 
comprehensive HIV care services in Nigeria. The clinic serves as a referral centre for health 
facilities within and outside Jos including local government areas of Plateau state and other states 
in the region. In the 2006 census, the population of Plateau State was 3,206,531, with the capital 
city of Jos having a population of approximately 900,000 (National Population Commission 
(NPC) Nigeria, 2006). 
 
1.5 Study significance 
The purpose of this study was to quantify the occurrence of ADRs and identify its risk factors in 
a clinic cohort of HIV-infected Nigerian adults on ART. The study also evaluated the effect of 
ADRs on viral suppression, a key HIV treatment outcome. Understanding the risk factors for 
ADRs in a given population could facilitate the identification of patients at risk of ADRs which 
could result in appropriate steps such as the use of alternative regimens or closer monitoring of 
patients for early detection and management of ADRs when they occur. This will contribute to 
the improved durability of first-line regimens (Perović-Mihanović et al., 2013).  In addition, 
understanding the association between ADRs and viral suppression could be exploited in the 
rational selection of ARV regimens to achieve maximal and durable viral suppression as well as 
foster retention of patients on treatment (Perović-Mihanović et al., 2013). Furthermore, data 
derived from within the country or region may have greater relevance and educational value and 
may encourage national regulatory decision-making (World Health Organization (WHO), 2002).  
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CHAPTER 2 
    LITERATURE REVIEW 
2.1 Principles of antiretroviral therapy 
The discovery of antiviral drugs, which can suppress HIV-1 replication to undetectable levels has 
been the most significant advance in the medical management of HIV-1 infection (Arts & 
Hazuda, 2012). As described in Arts & Hazuda (2012), antiretroviral drugs act by interfering 
with the replication of the HIV-1 virus by different molecular mechanisms. Based on their 
molecular mechanism and resistance profiles they are distributed into six distinct classes: (1) 
nucleoside-analog reverse transcriptase inhibitors (NRTIs), (2) non–nucleoside reverse 
transcriptase inhibitors (NNRTIs), (3) integrase inhibitors (INSTI), (4) protease inhibitors (PIs), 
(5) fusion inhibitors, and (6) coreceptor antagonists.  
 
The goal of ART includes the achievement of sustained virologic, immunologic, clinical, and 
epidemiologic control of HIV (World Health Organization (WHO), 2016b). It is expected that 
under optimal conditions, the use of ART should lead to rapid and sustained suppression of viral 
load down to < 400 copies /ml after 24 weeks and <50 copies/ml after 48 weeks of initiation of 
therapy (Federal Ministry of Health Abuja, 2016). With effective ART immune functions 
recovery is expected; with a progressive increase in CD4+ cell count at a rate of 50 to 100 
cells/µL /year. Additionally, there should be a significant improvement in clinical outcomes with 
reduced occurrence of morbid conditions and improved clinical indices (Federal Ministry of 
Health Abuja, 2016). 
 
The World Health Organization (WHO) approach to ART recommends the use of less toxic, 
more convenient and simplified ARV regimens, with a limited number of preferred first-line 
options that may be used across a range of populations (World Health Organization (WHO), 
2016). According to the WHO consolidated ART treatment guidelines for adults and adolescents, 
first-line ART for adults should consist of two nucleoside reverse-transcriptase inhibitors 
(NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI) or an integrase inhibitor 
(INSTI) (World Health Organization (WHO), 2016). The guidelines recommend efavirenz 
(EFV) + tenofovir (TDF) + either lamivudine (3TC) or emtricitabine (FTC) as a fixed-dose 
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combination as the preferred option to initiate ART (World Health Organization (WHO), 2016).  
WHO 2016 consolidated ART treatment guidelines for adults and adolescents also recommends 
that ART should be initiated in all adults living with HIV, regardless of WHO clinical stage and 
at any CD4 cell count. However, as a priority, ART should be initiated in all adults with severe 
or advanced HIV clinical disease (WHO clinical stage 3 or 4) and adults with CD4 count=350 
cells/mm3. 
 
2.2 Nigeria ART treatment guidelines 
In March 2017, the government of Nigeria adopted the WHO 2016 ART treatment guidelines 
for adults and adolescents. The key recommendations of the Nigerian ART guidelines 2016 
(Federal Ministry of Health Abuja, 2016) are summarized in Table 1.1 below. They include 
initiation of ART in all persons who test positive for HIV including children, adolescents, adults, 
pregnant and breastfeeding women, regardless of clinical and immunological stages of the 
disease. Other recommendations in the new guidelines cover the retesting of patients prior to 
initiation of ART, adoption of pre-exposure prophylaxis for individuals at high risk of acquiring 
the infection and addition of dolutegravir, efavirenz 400 mg and darunavir/ritonavir to the pool 
of approved antiretroviral drugs.  
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Table 2.1: Key recommendations of the Nigerian national guidelines for HIV 
prevention, treatment and care 2016 
Target population Recommendations 
What is new for 
HIV-positive 
adults and 
adolescents 
 Initiate ART in all adults and adolescents with a diagnosis of HIV. 
This is regardless of the clinical stage of the disease and also 
regardless of CD4+ cell count. 
 Dolutegravir (DTG) and Efavirenz (EFV) 400mg are new alternative 
options in first-line ART regimens.   
What is new for 
HIV-positive 
pregnant and 
breastfeeding 
women. 
 Initiation of ART for all HIV-positive and pregnant, post-partum and 
breastfeeding women, regardless of CD4+ cell count 
 Use of maternal ART throughout pregnancy and breastfeeding to 
reduce MTCT.  This ART treatment is for life 
 Repeat HIV testing for HIV-negative pregnant women in the last 
trimester 
 Viral load testing for pregnant women in the last trimester of 
pregnancy 
What is new for 
HIV-exposed 
infants 
 Infants born to mothers with HIV who are at high risk of acquiring 
HIV should receive dual prophylaxis with AZT (twice daily) and 
NVP (once daily) for the first 6 weeks of life, whether they are 
breastfed or formula fed 
 Breastfed infants who are at high risk of acquiring HIV, should 
continue infant prophylaxis for an additional 6 weeks (total of 12 
weeks of infant prophylaxis) 
What is new in 
prevention 
Pre-exposure prophylaxis is recommended for most at risk persons with 
special emphasis on serodiscordant couples and key populations 
Source: (Federal Ministry of Health Abuja, 2016, p. 43) 
2.2.1 Recommended ART Regimen for Adults, Adolescents and Children 
According to the Nigerian ART guidelines 2016 (Federal Ministry of Health Abuja, 2016), ART 
regimens are generally classified as first, second and third line. The first line regimens are used 
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in ARV-naive patients while second and third line regimens are used in individuals who have 
failed first and second line regimens respectively. Summary of antiretroviral regimen 
recommendations in the 2016 Nigerian ART guidelines is presented in Table 2.2 below. 
Table 2.2: Recommended first-line ART regimens for adults, adolescents, pregnant, 
breastfeeding women and children based on Nigerian 2016 ART guidelines 
First-line ART Preferred first-line 
regimen 
Alternative first-line regimens 
Adults 
 
 
 
TDF + 3TC (or FTC) 
+EFV 
 
 TDF + 3TC (or FTC) + *DTG  
 AZT + 3TC + NVP (or EFV) 
 TDF + 3TC (or FTC) + *EFV400 
 ABC +3TC +EFV 
 TDF + 3TC (or FTC) + NVP   
Pregnant/breastfeeding 
women 
TDF + 3TC (or FTC) 
+EFV 
 AZT + 3TC + EFV (or NVP) 
TDF + 3TC (or FTC) + NVP 
Adolescents (10-19 years) TDF + 3TC (or FTC) 
+EFV 
 TDF + 3TC (or FTC) + *DTG  
 TDF + 3TC (or FTC) + EFV400  
 AZT + 3TC + NVP or EFV 
 ABC + 3TC (or FTC) + *DTG 
 ABC + 3TC + (or FTC) +*EFV400  
 TDF + 3TC (or FTC) + NVP 
 ABC + 3TC (or FTC) + NVP 
Children 3 years to less 
than 10 years 
ABC + 3TC + EFV  ABC + 3TC + NVP  
 AZT + 3TC + EFV (or NVP)  
 TDF + 3TC (or FTC) + EFV (or 
NVP) 
Children less than 3 years ABC + 3TC + LPV/r  
AZT+3TC+LPV/r 
 ABC + 3TC + NVP 
 AZT + 3TC + NVP 
 AZT+3TC+RAL 
TDF, tenofovir; 3TC, lamivudine; FTC, emtricitabine; EFV, efavirenz 600mg; EFV400, 
efavirenz 400mg, DTG, dolutegravir; NVP, nevirapine;ABC, abacavir; 
LPV/r,lopinavir/ritonavir; RAL, raltegravir 
Source: (Federal Ministry of Health Abuja, 2016, p. 47) 
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2.3 Pharmacovigilance of antiretroviral medicines in low and middle-income countries 
It is now required that pharmacovigilance should be an integral part of every public health 
programme that uses medicines in order to optimize the use of scarce health resources and 
prevent potential medicine related harm (World Health Organization (WHO), 2006). 
Pharmacovigilance is defined as “the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other possible drug-related problems” 
(World Health Organization (WHO), 2006, p. 7). The major aim of pharmacovigilance is to 
safeguard public health by identifying medicine related risks and the risk factors in the shortest 
possible time so that harm can be avoided or minimized. When such information is 
communicated effectively, it can be utilized for the intelligent, evidence-based use of medicines 
and has the potential for preventing many adverse reactions. 
 
The use of antiretroviral medicines (ARVs) is associated with significant safety concerns 
including serious ADRs, with both short- and long-term effects. The practice of 
pharmacovigilance is well-established in most high-income countries, such as the United States’ 
Food and Drug Administration (FDA) Adverse Event Reporting System (U.S. Department of 
Health and Human Services. U.S. Food and Drug Administration (FDA), 2014) but the practice 
is limited and variable in low and middle-income countries (Strengthening Pharmaceutical 
Systems Program, 2011). The need for a robust pharmacovigilance system is particularly 
important in settings of rapid scale-up of new medications, as is the case of ART scale-up across 
many resource-limited settings, which has mostly involved the use of generic ART drug 
combinations that are not available in well-resourced settings (Gilks et al., 2006; Rosen, Fox, & 
Gill, 2007). Other conditions and factors in in low and middle-income countries which increase 
the safety concerns of ARVs “include the existence of comorbid conditions such as a high 
prevalence of tuberculosis (TB), malaria and other infections of all types; malnutrition; reliance 
on traditional and/or alternative therapies; insufficient numbers of trained doctors and 
pharmacists; irrational use of prescription medicines; and likelihood of medicine interactions” 
(Coulter, 2013, p. 4). Furthermore, due to shortage of trained manpower, some local systems for 
the delivery of healthcare may rely on people who have limited training, knowledge or expertise. 
Additionally, medicine regulatory systems in some low and middle-income countries are either 
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rudimentary or non-existent and are not adequately equipped to deal with medicine safety issues 
(Coulter, 2013).  
 
2.4 Pharmacovigilance of antiretroviral medicines in Nigeria 
An overview of pharmacovigilance activities in Nigeria as documented in the Global HIV/AIDS 
Initiative Nigeria (GHAIN) pharmacovigilance training manual (HUCE/PACE & NAFDAC, 
2009) indicates that the history of pharmacovigilance in Nigeria dates back to 1981. This 
essentially was the training of some staff of the federal ministry of health in pharmacovigilance 
at Uppsala Monitoring Centre (UMC) in Sweden. After that, some pockets of pharmacovigilance 
activity started in 1996; albeit on a very weak starting. In Sept 2004, the National 
Pharmacovigilance Centre (NPC), NAFDAC Nigeria was granted full membership as a 74th 
member country of the WHO International Drug Safety Monitoring Programme.  
 
There is a huge gap in drug safety reporting, including on ARVs, in Nigeria. For instance, 
between 2004 and 2009, the Nigerian NPC received only 879 individual case reports, of which 
78 (8.9%) were attributable to antiretroviral medicines. The Uppsala Monitoring Centre indicates 
that adequate reporting translates to 200 reports/million inhabitants/year. For Nigeria, this means 
that in any given year, we would expect to get 28,000 individual case reports but this is not the 
case (HUCE/PACE & NAFDAC, 2009). 
 
Recently, however, there has been an improvement in ADRs reporting due increase awareness 
created by NAFDAC and the involvement of public health programmes such as antiretroviral 
programmes in ADR reporting. A recent report on the patterns of adverse drug reaction signals in 
the Nigerian National Agency for Food, Drug, Administration and Control (NAFDAC) 
pharmacovigilance activities from September to November 2014 showed that a total of 100 
individual case safety reports were received within a period of three months. Out of this ART-
associated ADRs accounted for 24.3% of the case reports; which is a pointer that ART centres 
have been alerted to report ADRs in addition to suggesting that ADRs are common among 
patients on ART in Nigeria (Awodele, Ibrahim, & Orhii, 2016). This report brings to the fore the 
need to strengthen pharmacovigilance activities in antiretroviral programmes in Nigeria.  
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2.5 Specific adverse drug reaction reported with combination antiretroviral therapy 
Antiretroviral medicines (ARV), like most pharmaceutical agents, can result in ADRs that in 
some cases may be severe or life-threatening, especially if they are not recognized and managed 
on time (Mouton et al., 2015; Shet et al., 2014). Adverse drug reaction to ART are common and 
may occur immediately (soon after an antiretroviral medicine has been administered), early 
(within the first days or weeks of treatment) or late (after months of treatment), and vary in 
severity from mild to severe to life-threatening (Hawkins, 2010; Tadesse, Mekonnen, Tesfaye, & 
Tadesse, 2014). An ADR may be specific to the medicine or generic to the class of medicines 
used on a patient (Hawkins, 2010). The spectrum of ADRs according to the medicine classes are 
described below. 
 
2.5.1 Nucleoside Reverse-Transcriptase Inhibitors (NRTIs) related ADRs 
The majority of adverse events (AE) associated with NRTIs are due to mitochondrial toxicity 
with differences in the ability of different NRTIs to affect mitochondrial function (Subbaraman 
et al., 2007). Stavudine (d4T) and didanosine (ddI) are worse than zidovudine (AZT) while 
lamivudine (3TC) and abacavir (ABC) have the least toxicity of all (Subbaraman et al., 2007). 
Mitochondrial toxicities result in high rates of peripheral neuropathy, lipoatrophy, lactic acidosis, 
and pancreatitis (Subbaraman et al., 2007). The prevalence of these adverse events are presented 
below. 
 
Peripheral neuropathy (PN): This is a distal sensory neuropathy resulting from decreased 
mitochondrial function (Calmy, Hirschel, Cooper, & Carr, 2009). About 10% to 21% of persons 
exposed to d4T developed peripheral neuropathy in developed countries (Van-Oosterhout et al., 
2005). However, 56% of patients in a Malawian cohort developed peripheral neuropathy while 
receiving d4T therapy (Van-Oosterhout et al., 2005). A PN prevalence of 63% was reported 
among patients on first-line ART in Zimbabwe (Nemaura et al., 2012), while studies in Nigeria 
reported prevalence ranging from 12.7% to 30% (Agu et al., 2013; Bassi et al., 2017; Eluwa et 
al., 2012). Symptoms usually resolve after prompt discontinuation of d4T therapy but may be 
persistent in a subset of patients. Currently, d4T is not recommended as part of the first line 
http://etd.uwc.ac.za
19 
 
regimen (World Health Organization (WHO), 2016b). 
 
Lipodystrophy and metabolic complications: Lipoatrophy is characterized by loss of 
subcutaneous fat in the extremities, buttocks, and face (Murphy, Sunpath, Kuritzkes, Venter, & 
Gandhi, 2007). Although AZT sometimes causes lipodystrophy, d4T is more strongly associated 
with this adverse effect (Subbaraman et al., 2007). Prevalence of d4T-associated lipodystrophy 
as high as 50% to 63% has been reported in western studies (Subbaraman et al., 2007). African 
studies have reported lower prevalence: 0.8% in a Nigeria cohort (Agu et al., 2013), 24.8% of 
patients in a Rwandan cohort (Van-Griensven et al., 2010), and 38% in Zimbabwe (Nemaura et 
al., 2012). The diagnosis of stavudine-associated lipodystrophy might be complicated by 
malnutrition which commonly presents as lipoatrophy (i.e., fat loss in the cheeks, arms, and 
buttocks) (Murphy et al., 2007).  
 
Lactic acidosis: Lactic acidosis is a rare (0.85 – 2.7 per 1,000 person-years) but life-threatening 
condition, which clinically manifests as subacute onset of nausea, fatigue, weight loss, 
abdominal pain, dyspnoea and eventual circulatory collapse (Calmy et al., 2009). Rates as high 
as 20% have been described in southern Africa (Wester et al., 2007). Factors associated with 
lactic acidosis are older age, female sex, high body mass index, lipoatrophy, low CD4 and T-cell 
count, hypertriglyceridemia and use of d4T and ddi; although this AE has been described with all 
NRTIs except ABC (Bonnet et al., 2005; Wester et al., 2007). 
 
Myelosuppression: Anemia is an important early AE primarily associated with AZT-containing 
regimens and typically develops in the first six months of therapy and can be severe, particularly 
when AZT is introduced in individuals with advanced immunosuppression (Murphy et al., 2007). 
Studies from Coˆte d’Ivoire, Haiti, and India have found rates of AZT-related anaemia of 3% – 
12% (Subbaraman et al., 2007). In Nigeria, the reported prevalence ranged from 2.2% to 7% 
among patients on first-line ART (Agu et al., 2013; Reginald et al., 2012). Risk factors for 
anaemia include high AZT dosage, increased treatment duration, low CD4 cell count, and 
preexisting anaemia (Murphy et al., 2007).  
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2.5.2 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) related ADR 
Toxic effects frequently associated with NNRTIs such as nevirapine (NVP) and efavirenz (EFV) 
include hypersensitivity reaction, hepatotoxicity, neuropsychiatric disorders and immune 
reconstitution syndrome (Subbaraman et al., 2007). 
 
Hypersensitivity reaction: most commonly reported with NVP and may be characterized by a 
rash, fever, symptomatic hepatitis, and eosinophilia (Murphy et al., 2007). This AE most 
commonly occurs in the first 16 weeks of therapy and can occasionally progress to fulminant, 
fatal liver failure (Murphy et al., 2007). Risk factors for hypersensitivity reaction include a high 
baseline CD4 cell count of >250 cells/mm3 as well as female sex (Murphy et al., 2007). 
Prevalence of the hypersensitivity rash of between 3% to 26% has been reported in studies from 
developed and developing countries (Subbaraman et al., 2007). The reported prevalence in 
Nigerian cohorts ranged from 16% to 26% (Agu et al., 2013; Eluwa et al., 2012; Reginald et al., 
2012). 
 
Hepatotoxicity: this is characterized by transaminase level elevation and symptomatic hepatitis 
and is most frequently associated with NVP than EFV (Murphy et al., 2007; Sanne et al., 2005). 
Incidence of drug-related hepatitis in the United States (US) and European studies ranges from 
1% to 10% (Pollard, Robinson, & Dransfield, 1998; Stern JO, Robinson PA, Love J, Lanes S, 
Imperiale MS, 2003), while a higher incidence of 17% was reported in a South African study 
(Sanne et al., 2005). The incidence of hepatotoxicity in Nigerian patients is poorly described but 
a study reported a jaundice prevalence of 4% (Reginald et al., 2012). 
 
Neuropsychiatric disorder: Neuropsychiatric disorders including psychosis-like behavior, 
suicide, severe delusions, dizziness, insomnia, impaired concentration, irritability, nervousness, 
somnolence, abnormal dreams, and hallucinations are usually classified as CNS symptoms are 
the most common and significant adverse effects associated with EFV therapy (Abah et al., 
2015; Subbaraman et al., 2007). In US and European cohorts, 50% of patients have 
neuropsychiatric symptoms after initiating EFV therapy, but these symptoms usually resolve 
within one month (Subbaraman et al., 2007). A study from Cote d’Ivoire found a high 
neurotoxicity rate of 69% after initiation of therapy with EFV (Danel et al., 2003), while the 
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incidence rate in a Nigerian study was 30 per 1000 person-years of ART (Abah et al., 2015). 
Risk factor for EFV-related neurotoxicity includes female gender, age < 40 years, advanced HIV 
disease (WHO stage 3 or 4 diseases), and use of EFV with AZT or d4T (Abah et al., 2015). 
Some studies suggest that people of African ancestry with a variant of hepatic enzyme CYP2B6 
may experience slower clearance of EFV from plasma and increased neurotoxicity (Barrett et al., 
2002; Haas et al., 2004; Pfister et al., 2003; Sarfo et al., 2014). 
 
2.6 Effect of adverse drug reactions on key HIV treatment outcomes 
2.6.1 Adverse drug reactions and medication adherence 
A sufficiently high level of adherence (>90%) to combination antiretroviral therapy is required to 
achieve and sustain viral suppression and to prevent disease progression and death in HIV-
infected patients (Bangsberg et al., 2000; Lucas et al., 1999; Oreagba et al., 2014; Paterson et al., 
2000). Studies have shown that achieving and sustaining the high level of adherence required for 
optimal virologic control is a major challenge to many HIV-infected patients (Adeyemi, 
Olaogun, & Adesola, 2008; Bärnighausen et al., 2011; Monjok, Smesny, Okokon, Mgbere, & 
Essien, 2010; Ostrop, Hallett, & Gill, 2000). Medication side effect has been consistently 
reported in several studies as one of the factors that negatively impact on treatment adherence 
(Shet et al., 2014; Syed et al., 2015; Tadesse et al., 2014). Although Nigerian studies on the 
effect of ADRs on treatment adherence are scarce, in one Nigerian study, 76% of patients 
indicated medication side effect as reasons for not taking their medication (Uzochukwu et al., 
2009).  
 
2.6.2 Adverse drug reaction and regimen modification/discontinuation 
In resource-limited settings, regimen durability is critical to treatment success due to limited 
treatment options (Murphy et al., 2007). A study conducted at Jos University Teaching Hospital 
ART Centre reported a high rate of regimen modification of 83% and a significant association 
between regimen modification and ADRs (Abah, et al., 2015). In another study at the same 
hospital, drug toxicity/side was the most frequent (34%) reason for modification of first-line 
regimen (Falang et al., 2008). In agreement with the finding of Falang et al., 2008, several other 
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studies have reported ADRs as the most frequent reason for regimen 
modification/discontinuation among patients on combination antiretroviral therapy. The 
proportion of regimen modification /discontinuation due to ADRs was 27% in south Indian 
adults (Sivadasan et al., 2009), 30% in Ethiopians (Teklay, 2013), 60% among Scandinavians 
(Leutscher, Stecher, Storgaard, & Larsen, 2013), 66% in Western Kenya (Inzaule et al., 2014), 
and as high as 95% in Rio de Janeiro, Brazil (Torres, Cardoso, Velasque, Veloso, & Grinsztejn, 
2014). What is not very clear from these studies is the impact of the regimen modification on 
virologic outcomes. 
 
2.6.3 Adverse drug reactions and virological failure 
One of the goals of ART is to achieve maximal and durable viral suppression. Attaining an 
undetectable viral load is a major indicator of treatment success. The WHO recommends viral 
load testing as the preferred monitoring approach to diagnose and confirm ARV treatment failure 
(World Health Organization (WHO), 2016). In an earlier single institutional Nigerian study, 
Taiwo et al (2010) found that up to 50% of patients do not achieve undetectable viral load in one 
year of ART. In contrast to the earlier Nigerian study (Taiwo et al., 2010), a recent multicenter 
cohort study involving 70,002 patients in Nigeria reported that a high proportion (85%) of 
patients on ART achieved viral suppression (Meloni et al., 2016), with 69% of the patients 
achieving suppression within six months of ART. The differences in the viral suppression rates 
reported across different studies in Nigeria highlights the importance of continuous monitoring 
of virologic outcome in a cohort of patients on ART, as the virologic success rates might change 
over time and may be influenced by several factors.  The impact of ADRs on viral suppression is 
poorly described in the literature. This is despite that ADRs is a significant prognostic factor for 
poor adherence; an independent predictor of virologic failure. An Indian study evaluated the 
effect of ADR on treatment success among Indians and found no significant association between 
the occurrence of severe ADR and the attainment of undetectable viral load at 12 and 24 months 
of ART (Shet et al., 2014). However, the study did not evaluate the effect of mild ADRs on viral 
suppression, despite that mild ADRs were very common in the study. The relationship between 
ADRs and viral suppression has not been sufficiently described and requires further exploration. 
This is particularly important considering the high proportion of patients on ART who 
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experience an ADR as described above. 
 
2.6.4 Prevention and management of adverse effects of antiretroviral therapy 
Available evidence already described above shows that adverse events are common with all 
available antiretroviral agents. Therefore, it is critical to anticipate, recognize, and manage them 
promptly when providing primary care for HIV-infected patients to mitigate the possibility of 
negative outcomes. Patients should be informed of potential side effects during consideration of 
the first regimen, and possible management strategies in case of adverse events. Known profile 
of adverse events associated with ARV medicines should be considered in the initial treatment 
decision. For instance, if the medication is associated with CNS side effects which may impact 
psychomotor function, as in the case of EFV, it may be risky to initiate patients whose job 
demand high mental alertness on the medicine. Also, medications associated with a high risk of 
diarrhoea may not be the best option for patients who are experiencing diarrhoea or HIV-related 
wasting. Considering the impact of ADRs on medication adherence and the unforgiving nature of 
HIV infection with regards to adherence, it is essential to establish the patient's readiness for 
HAART before the first prescription, including knowledge of, and treatment for possible adverse 
events (Max & Sherer, 2000). Similarly, adherence is not a “one-shot” problem and ADRs can 
occur anytime in the course of therapy; repeated monitoring, education, and interventions are 
therefore required throughout the period of ART (Max & Sherer, 2000).
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2.6.5 Conceptual framework for studying effect of adverse effects on virologic failure 
Available evidence suggests that acute and chronic toxicities associated with antiretroviral 
medicines may lead to dose interruption and discontinuation of therapy (Leutscher et al., 2013; 
Prosperi et al., 2012). Poor adherence to treatment and treatment discontinuation are risk factors 
for treatment failure, and development and selection of drug-resistant virus (Keiser et al., 2007). 
The development of drug resistance has public health implications of transmission of drug-
resistant HIV viruses and the need to implement treatment with much more expensive second-
line and salvage therapies. This could be a major threat to ART programme success and 
sustainability in sub-Saharan Africa where most of the programmes are donor dependent (Keiser 
et al., 2007; Max & Sherer, 2000; Moreno et al., 2010). Drug refill adherence was used as a 
proxy for medication intake in this study since poor adherence to therapy is on the causal 
pathway of virologic failure. 
 
Although it is expected that poor adherence due to ART-associated ADRs would result in poor 
viral response owing to the significant prognostic effect of poor adherence on treatment failure, 
studies on the impact of ADRs on viral outcomes are scarce. Key factors to be considered while 
studying the magnitude of ADRs and the association between ADRs and virologic failure are 
shown in the conceptual framework in Figure 2.1 below.  
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Figure 2.1: Conceptual framework for studying antiretroviral medicine related ADR 
and its effect on virologic failure 
 
In conclusion, ADRs related to ART are common; however, the magnitude of ADRs and their 
impact on treatment success particularly durable or sustained viral suppression in patients on 
ART in Nigeria have not been fully explored. This study utilized longitudinal data to describe the 
incidence and spectrums of ADRs associated ARVs and evaluate the impact of ADRs on the 
achievement of sustained HIV suppression. 
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       CHAPTER 3 
 AIMS AND OBJECTIVES 
3.1 Aims 
The aim of the research was to describe the frequency, types, and risk factors for clinical ADRs 
due to ART, and to assess the effect of ADRs on virologic failure among patients on ART at Jos 
University Teaching Hospital (JUTH) HIV Clinic.  
3.2 Objectives: 
1. To describe the incidence of clinical ADRs in a clinic cohort of adults on ART at the 
study site 
2. To describe the types of clinical ADRs among adults on ART at the study site 
3. To assess the association between patients’ pre-ART demographic, clinical, and regimen 
characteristics and the risk of clinical ADRs due to ART 
4. To identify baseline demographics, clinical, and regimen characteristics that 
independently predict the risk of virologic failure among patients on ART 
5. To measure the likelihood of developing virologic failure in patients who experience 
clinical ADRs due to ARVs  
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CHAPTER 4 
   METHODOLOGY 
4.1 Study design 
A retrospective cohort study design was utilized to address the study aim. Utilizing longitudinal 
data stored in an electronic medical record system, it was possible to describe the incidence rate 
and profile of ARV medicine-related clinical adverse reactions in our patient cohort as well as 
retrospectively assess the risk factors for ADRs. The use of retrospective data also made it 
possible to examine the association between two time-varying variables such as ADR and 
virologic failure. The chosen approach offered the advantage of being cheap and quick to 
implement, as data had already been collected. Also, it was more efficient for measuring time-
varying exposures such as ADRs and outcomes like virologic failure with variable induction and 
latency periods. Additionally, the study design was suitable for studying rare exposures and 
outcomes. Furthermore, the design made it possible to study a large number of participants and 
with a long history of follow up (Bonita, Beaglehole, & Kjellström, 2006). The introduction of 
an electronic medical record system at the study site in 2004 resulted in significant 
improvements in the quality of data which was used to address the research questions.  
4.2 Study Setting 
Jos University Teaching Hospital (JUTH) is a Federal Tertiary Healthcare Facility located in the 
cosmopolitan city of Jos in North-central Nigeria. The HIV treatment facility was established by 
the Federal Government of Nigeria in January 2002 as part of an expanded response to care and 
support for people living with HIV (PLWHA) (National Agency for the Control of AIDS 
(NACA), 2014). Rapid scale-up of ART services at JUTH started in 2004 through collaboration 
between JUTH, the University of Jos and the Harvard School of Public Health (HSPH)/AIDS 
Prevention Initiative in Nigeria (APIN) program, which was supported by the U.S. President’s 
Emergency Plan for AIDS Relief (PEPFAR) grant.  
 
Services at JUTH adult HIV clinic are provided by a complement of over 100 health and non-
health professionals including doctors, pharmacists, nurses, laboratory scientists, dieticians, 
medical social workers. Non-health professionals include administrative officers, accountants, 
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secretaries, clerks, and cleaners. Services provided at the clinic include HIV counselling and 
testing, prevention of mother to child transmission of HIV (PMTCT), paediatric HIV care, and 
treatment and support for PLWHAs. At the time of this study, all services including clinical, 
pharmacy and laboratory services are offered free to patients. 
 
4.3 Study population  
The study population included HIV-infected adults ≥18 years of age accessing treatment at the 
treatment site between June 2004 and February 2012. The clinic population was drawn mostly 
from the North Central geopolitical zone of Nigeria and included various tribes and socio-
economic strata in the society. Also, the cosmopolitan nature of Jos makes the population reflect 
the various ethnic nationalities in Nigeria.  
 
Inclusion criteria: HIV-infected patients’ ≥18 years of age who were enrolled in the 
HSPH/APIN program, treatment naïve at enrolment and receiving first-line ART at JUTH for a 
minimum of 12 months’ duration between June 2004 and February 2012. The starting period of 
June 2004 was chosen as the study starting point as it coincides with the introduction of 
electronic medical record in the treatment program, while February 2012 was used as the study 
endpoint because it marked a major transition period of transition in the HIV treatment program 
at JUTH. Hence, the study period of June 2004 and February 2012 assured access to usable and 
accurate data. Treatment naïve patients on first-line therapy were included as the initial ART 
regimen affords the best opportunity to attain maximal viral suppression (Asboe et al., 2012; 
Booth et al., 2014).  
 
Exclusion criteria: Those who picked up ARVs only once at the pharmacy and those with 
insufficient baseline data such as missing the first ARV dispensing date were excluded.  
 
4.4 Sample size 
A total of 12,115 patients who met the inclusion criteria were included in the study. The 
availability of an electronic medical record system made it possible to select eligible participants.  
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4.5 Sampling procedure 
All patients enrolled in care at the study site who met the inclusion criteria were included in the 
analyses. For ART-naïve patients, eligibility for ART in the HIV treatment program followed the 
Nigerian National Guidelines (Federal Ministry of Health (FMoH) [Nigeria], 2010; Federal 
Ministry of Health (FMoH) Nigeria, 2007) which closely mirrored the World Health 
Organization (WHO) Guidelines at the time of patient enrollment (Gilks et al., 2006; World 
Health Organization (WHO), 2010, 2013, 2016b). Beginning in 2004, patients were considered 
eligible for ART if their CD4+ cell counts dropped below 200 cells/mm3 or if symptomatic with 
CD4+ cell counts below 350 cells/mm3; from 2010 CD4+ cell counts eligibility was below 350 
cells/mm3 regardless of symptoms. The first line therapy was based on the Nigerian National 
Adult ART Guidelines (Federal Ministry of Health (FMoH) Nigeria, 2007, 2010) and involves 
combination antiretroviral therapy consisting of two nucleoside backbone of either AZT 
(AZT)/lamivudine (3TC), stavudine (d4T)/3TC, ABC (ABC)/3TC, (DDI)/3TC or Tenofovir 
(TDF)/3TC in combination with either NVP  or efavirenz (EFV).  
 
4.6 Data collection and processing 
Patients’ demographic, clinical, laboratory and prescription records were maintained in an 
electronic database developed for use in the HSPH/APIN program (FileMaker Pro, v10; 
FileMaker, Inc, Santa Clara, California, USA).  The facility data manager carried out the data 
extraction with the aid of a data extraction form (Appendix I). A data extraction form was 
utilized to ensure that data on all required variables were extracted. The extracted data were 
exported to Microsoft Excel for data cleaning.  
Independent variables (exposure):  baseline or pre-treatment demographic (age, sex, 
education, employment status, marital status, and enrollment year), clinical (ART regimen, 
WHO clinical stage, TB co-infection, HBV and/or HCV co-infection,  CD4+ cell count, viral 
load), adverse drug reactions, and drug refill adherence. 
CD4 cell count, viral load data were obtained at baseline and at 24, 48, and 72 weeks of ART, 
while adherence was measured at 24, 48, and 72 weeks of ART. Age, CD4 cell count, viral load, 
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duration of ART, adherence to drug refill schedules were measured on a continuous scale. 
Duration of ART was determined from the first ARV dispensing date and the date of last drug 
refill, while adherence to ART determined using drug refill adherence. Drug refill adherence was 
calculated automatically by a computerized pharmacy appointment system which utilized the 
total number of days that the patient was behind for the drug- refill visits. Percentage of 
cumulative adherence was estimated by the following formula: The total number of days behind 
schedule divided by the total number of days the patient was assumed to be exposed to ART 
given the dispensed number of pills multiplied by 100 (Abah et al., 2014; El-Khatib et al., 2011).  
Dependent variables (outcome): The main outcome measure was virologic failure defined as 
plasma viral load above 1000 copies/mL based on 2 consecutive viral load measurements after 6 
to 12 months of ART initiation (World Health Organization (WHO), 2016). Viral load is the 
recommended preferred monitoring approach to diagnose and confirm treatment failure in 
patients on ART (World Health Organization (WHO), 2016). To evaluate the risk factors for 
ADRs, clinical ADRs will also be treated as an outcome measure.  
Definitions of exposures and outcomes 
Adverse drug reactions (ADRs)- defined as clinical ADRs documented on the ADR report form 
or toxicity form using International Classification of Diseases 10 (ICD-10) classification for 
ADRs (Hohl, Karpov, Reddekopp, & Stausberg, 2014). If a clinical ADR was identified, 
clinicians completed a program-specific toxicity form, which included detailed information 
about the suspected medication-related toxicity. The toxicity form contains an extensive 
checklist of symptoms categorized by body system. ADRs were graded on a four-point scale 
using the WHO severity grading (World Health Organization (WHO), 2005); Grade 1 was 
classified as “mild” and no limitation of daily activities; Grade 2 classified as “moderate” with 
mild to moderate limitation of activities; Grade 3 classified as “severe” with marked limitation of 
activities and Grade 4 classified as “life-threatening” with extreme limitation of activities and 
significant medical intervention.  
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Baseline: the time of ART initiation. Baseline clinical assessments or laboratory evaluations for 
naïve patients were the closest measurements to, and up to six months before or 0.5 months after, 
their first ART pick-up date. 
Early virologic failure: for the purpose of this study, early virologic failure was defined as 
having an HIV viral load of >1000 copies/Ml after ≥6 months (24 weeks) of ART (Federal 
Ministry of Health Abuja, 2016). 
Late virologic failure: for the purpose of this study, late virologic failure was defined as having 
an HIV viral load of >1000 copies/Ml after ≥ 18 months (72 weeks) of ART 
4.7 Data analysis 
Descriptive analyses, including frequencies and proportions, were reported for categorical 
variables. An initial exploratory analysis of continuous variables was conducted to examine their 
distribution. Normally distributed continuous variable such as age was reported as mean with 
standard deviation, while CD4 cell count and viral load which were skewed were reported as 
median with interquartile range (IQR). To calculate the incident rate of ADRs, patients were 
censored at the first occurrence of an ADR, discontinuation of ART (defined as failure to pick 
ARV for any reason for duration ≥12 months) or the end of the observation period, defined as the 
end of February 2012. The incidence rate of ADRs was determined by dividing the number of 
incident events by the total observation time contributed by patients. Each patient contributed 
observation time from baseline (defined as the start date of ART) to censor date. The total time 
of observation contributed by each patient was summed up to obtain the total person-years of 
observation. Bivariate analysis of factors associated with ADRs was performed using Pearson 
Chi-Square. For the bivariate analysis, age, CD4 cell count, and viral load were categorized. Age 
was categorized based on age quartiles, CD4 cell count based on WHO immunological disease 
staging (Gilks et al., 2006; World Health Organization (WHO), 2010, 2013, 2016b), while viral 
load was categorized according to a strata used in a previous study in a similar setting (Meloni et 
al., 2016). Baseline characteristics that were significantly associated with ADRs in the bivariate 
analysis (p <0.05), as well as those that are clinically relevant or have biological plausibility to 
affect ADRs, were included in a multivariable logistic regression model to identify independent 
predictors ADRs. Age was included in the model as a continuous variable. A multivariable 
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logistic regression model was used instead of a time to event analysis to assess independent 
predictors of ADRs due to the limitations of the study design; the study is not a well-controlled 
longitudinal, follow up study in a dynamic cohort. Factors associated with virologic failure at 24 
and 72 weeks of ART were assessed by chi-square analysis. The time point of 24 and 72 weeks 
was chosen for analysis of early and late virologic failure to provide sufficient internal between 
points of analysis of early and late virologic failure. The association between major ADRs 
identified in previous studies such as lipodystrophy, anaemia, peripheral neuropathy, and skin 
disorders (Kenneth A Agu et al., 2013; Awodele et al., 2016; Ogwuche et al., 2014) and 
virologic failure was examined by chi-square analysis. A multivariable logistics regression 
analysis was performed to adjust for the effect of confounders on virologic failure. Only 
variables that were significantly associated with virologic failure to a p <0.05 were included in 
the multivariate model.  All statistical tests were two-tailed and a p-value <0.05 considered 
statistically significant. Stata version 13 (College Station, TX) was used for the statistical 
analyses. 
 
4.8 Validity 
To ensure validity, standard definitions for the outcomes and exposures were used. A virologic 
failure (the primary outcome measure) was defined using WHO definition for virologic failure – 
a viral load above 1000 copies/mL based on two consecutive viral load measurements in three 
months; with adherence support following the first viral load test, after at least six months of 
antiretroviral therapy (World Health Organization (WHO), 2016).  Viral load measurement at 
different time points was utilized for the analysis since viral load is a time-varying covariate. 
 
Clinical ADRs were documented by clinicians using case definition of ADR (Coulter, 2013), 
Adherence to ART, an important confounder of virologic failure, was measured and documented 
at JUTH HIV clinic by means of medication refill adherence - a measure which had been 
previously reported to predict virologic outcomes in the study site (Abah et al., 2014). To 
minimize the effect of differences in adherence due to different duration of ART exposure, 
percentage adherence at a specific time (24, 48, or 72 weeks) was used. 
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4.9 Reliability 
In order to improve the reliability of the study, potential confounding variables were measured 
and adjusted for statistically for their impact on the relationship between exposure (ADRs) and 
outcome (virologic failure). Data extraction was done using a detailed data extraction form by an 
experienced data manager. Furthermore, extracted data was independently checked by the 
researcher for consistency. Finally, exploratory data analysis was conducted to determine if any 
data has been entered incorrectly (out of range values), to check for missing values and deciding 
how to deal with these values, as well as to check for outliers and test for normality. 
 
4.10 Generalizability 
The HSPH/APIN ART program at JUTH is one of the largest HIV treatment cohorts in Nigeria.  
Results from the study can be extrapolated to other ART settings using first-line ART in Nigeria 
as the clinic population cut across various tribes, socio-economic strata in the society which 
reflect the various ethnic nationalities in Nigeria. Extrapolation of the results to other settings 
should, however, be done with caution as differences may exist between individuals’ in response 
to medicines, and quality of care across programmes which might impact on the study outcomes.  
 
4.11 Ethics 
The study protocol was submitted to the University of Western Cape (UWC) Research Ethics 
Committee and approval obtained (Appendix II). In addition, ethics approval for use of data was 
obtained from the Jos University Teaching Hospital ethical committee (Appendix III), and the 
use of secondary data was approved by Harvard School of Public Health (Appendix IV). A final 
approval for data extraction was obtained from the study facility (AIDS Prevention Initiative 
(APIN) JUTH HIV clinic) (Appendix V). As the study involved the use of retrospective data, 
there was no direct harm to patients. To ensure confidentially of patients’ records, data extracted 
from the electronic medical record system was de-identified and stored in an encrypted format in 
a secure computer system accessible only to the researcher and supervisor. The results of the 
study could be of direct benefit to subsequent patients as data generated can be exploited in the 
rational selection of ARV regimens to achieve maximal and durable viral suppression as well as 
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foster retention of patients on treatment. The findings of the study will be disseminated through a 
published thesis and other scholarly publications which will be accessible to the public.  
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CHAPTER 5 
          RESULTS 
5.1 Descriptive analysis 
The flow diagram below (Figure 5.1) summarizes the distribution of study patients according to 
their initial antiretroviral treatment regimen. Between June 2004 and February 2012, 16,012 
adults were commenced on ART at the study site. Of these, 3,897 (24.3%) were excluded from 
the analysis; 1,943 (12.1%) were treatment-experienced at enrolment and 1,954 (12.2%) had 
only one pharmacy pick-up. A total of 12,115 (87.9%) patients were included in the final 
analysis, of which the majority (98.5%) were on standard first-line non-nucleoside reverse 
transcriptase inhibitor (NNRTI) based ART. Most of the patients (76.4%) received NVP based 
regimen at treatment initiation. The most commonly used ARV regimen for treatment initiation 
was with AZT-3TC-NVP (n=5,105, 42.1%) followed by TDF-3TC-NVP or TDF-FTC-NVP 
(n=2,527, 20.8%) and EFV-3TC-TDF (n=1,529, 12.9%) respectively. 
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Figure 5.1: Flow diagram of patients and ART regimen received at treatment initiation 
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5.2 Characteristics of adults treated with first-line antiretroviral therapy at the study 
site, June 2004- February 2012 
Table 5.1: Socio-demographic characteristics of –study participants (N=12,115) 
 Characteristics  Sub-group Frequency Percent 
Sex Females 8150 67.27 
  Males 3965 32.72 
Age, mean ± SD, years  All patients 35.77± 9.10  
 Female 33.71±8.48  
 Males 40.02±8.85  
Age range, years 15-24 711 5.86 
 25-45 9445 77.96 
 >45 1911 15.77 
 Missing data 48 0.39 
Marital Status Divorced/Separated 995 8.21 
  Married 6443 53.18 
  Single 2375 19.60 
  Widowed 1958 16.16 
 Missing data 344 2.84 
Highest Education No formal education 1993 16.45 
  Primary 2473 20.41 
  Secondary 3651 30.14 
  Tertiary 3654 30.16 
 Missing data 344 2.84 
IQR, interquartile range 
 
Table 5.1 shows that majority of the study participants were females (67%) and young adults in 
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the age bracket of 25 to 45 years (78%). The mean age of females was significantly lower than 
that of male participants (34 versus 40 years; p <0.001). Just over half of the participants were 
married, while less than one-quarter (20%) were never married. Most participants were educated; 
with secondary and tertiary education reported as the highest educational attainment by one-third 
of the study participants, while less than 20% had no formal education. Clinical characteristics of 
participants prior to the commencement of ART are summarized in Table 5.2. 
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Table 5.2: Pre-treatment clinical characteristics of study participants (N=12,115) 
 Characteristics  Sub-group Frequency (N) Percent (%) 
WHO disease stage 1 3964 32.72 
  2 3567 29.44 
  3 3085 25.46 
  4 711 5.87 
 Missing data 788 6.50 
CD4 cell count, cell/mm3 ≤100 4240 35.00 
  101 - 199 3921 32.36 
  200 - 349 2888 23.84 
  ≥350 959 7.92 
 Missing data 107 0.88 
 Median (IQR) 142 (72 – 230)  
Viral load, copies/ml ≤10,000 3226 26.63 
  10,001-100,000 4664 38.50 
  >100,000 4164 34.37 
 Missing data 61 0.50 
 Median (IQR) 43, 680 (8,475 – 
160,213) 
 
Hepatitis B status Negative 8406 69.39 
  Positive 2208 18.23 
 Missing 1501 12.39 
Tuberculosis infection No 1388 11.46 
  Yes 573 4.73 
 Missing 10154 83.81 
WHO, World Health Organisation, IQR; interquartile range 
 
Overall, the median baseline CD4+ cell count was low and 35% of the participants had severe 
immunosuppression (CD4+ cell count ≤100 cells/mm3) at baseline.  Hepatitis B and HIV co-
infection was less than 20%, while a high proportion of the participants (84%) did not have a 
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documented tuberculosis (TB) result. Of those with available TB data, only about 5% of were 
positive for TB. 
5.3 Trend and pattern of patient enrolment on antiretroviral therapy June 2014 –
February 2012  
The trend in new patient enrolment on ART showed an increase in new patient enrolment from 
180 patients in 2004 to 2180 patients in 2005 as shown in Figure 5.2. New patient enrolment 
peaked in 2006 and then dropped to under 1000 patients per year by 2010.  In the figure, year 
2012 enrolment was low as it only reflects two months of data.  
 
 
Figure 5.2: Trend in new patient enrolment on antiretroviral therapy 
 
As shown in Figure 5.3, the combination of stavudine/lamivudine/nevirapine was the only 
antiretroviral (ARV) regimen used in 2004. However, from 2005 the number of ARV regimens 
increased to five and peaked at 12 regimens in 2006. By 2010 there were only three regimens. In 
line with WHO recommendations, the use of stavudine-based regimens decreased in 2006, and 
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was phased out completely in 2007. Between 2006 and 2008 zidovudine-based regimen was the 
dominant regimen used, while tenofovir (TDF)-based regimen was introduced in 2005 and its 
use peaked in 2008.  
 
 
Figure 5.3: Distribution of initial antiretroviral regimen by year of enrolment 
 
5.4 Incidence of adverse drug reactions in the study cohort 
Table 5.2 shows that the incidence rate of any ADR was highest during the first year of ART 
(41/1000 py), after which it dropped sharply between the first and second year, and then 
increased to 21/1000 py between the second and third year. After the third year of ART, there 
was a consistent decline in the incidence rate of ADRs, with the lowest incidence rate of 5/1000 
py recorded between the sixth and seventh year of treatment. However, the rate increased slightly 
to 8/1000 py between the seventh and eighth year after the drop observed. A comparison of the 
incidence rate between first and subsequent years of ART showed that the risk of ADRs almost 
tripled during the first year compared to the subsequent years (41 per 1000 py versus 14 per 1000 
py, for ≤1 year and >1 of ART; crude incidence rate ratio, 2.87 (95% CI: 2.53-3.24)) 
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Table 5.3: Incidence of adverse drug events in patients on first-line ART at Jos 
University Teaching Hospital HIV clinic June 2004 and February 2012 
Period, 
years 
Person-
years (py)   
Number of 
events 
Incident rate  per 1000 
py (95% CI) 
Crude incident rate 
ratio (95% CI) 
0   -   1 10578 430 40.65 (36.98 - 44.68) Reference 
1   -   2 8868 91 10.26 (8.36 - 12.6) 3.96 (3.21 - 4.89) 
2   -   3 7413 167 22.53 (19.36 - 26.22) 1.80 (1.51 - 2.45) 
3   -   4 6147 116 18.87 (15.73 - 22.64) 2.15 (1.76 - 2.63) 
4   -   5 4930 67 13.59 (10.7 - 17.27) 2.99 (2.34 - 3.82) 
5   -   6 3582 28 7.82 (5.4 - 11.32) 5.20 (3.69 - 7.32) 
6   -   7 2370 11 4.64 (2.57 - 8.38) 8.76 (5.33 - 14.37) 
7   -   8 1033 8 7.75 (3.87 - 15.49) 5.25 (2.81 - 9.81) 
>   8 112 0    
Total 45034 918 20.38 (19.11 - 21.75)  
 
CI, confidence interval 
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5.5 Prevalence and types of adverse drug reactions among adults on ART at Jos 
University Teaching Hospital (2004-2012) 
A total of 918 out of the 12,115 (7.6%) patients experienced at least one ADR. The type of 
ADRs and the severity shown in Table 5.4 illustrates that compared to other ADRS, severe 
ADRs were more common (4.5%), followed by moderate (2.6%), and mild ADRs (0.8%), while 
life-threatening ADRs were rare (0.1%).  
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Table 5.4: Prevalence of specific adverse drug events in 12,115 patients on first-line 
ART at Jos University Teaching Hospital HIV clinic June 2004 to February 2012 
 Group/Specific  
adverse drug reactions 
Mild  
N (%) 
Moderate 
N (%) 
Severe 
N (%) 
Life-threatening 
N (%) 
All  
N (%) 
All events, n (%) 98 (0.81) 312 (2.58) 532 (4.47) 12 (0.10) 957 (7.90) 
Metabolic symptoms 33 (0.27) 148 (1.22) 144 (1.18) 1 (0.01) 326 (2.69) 
Lipodystrophy 29 (0.24) 144 (1.19) 141 (1.16) 1 (0.01) 315 (2.6) 
Gynaecomostia 4 (0.033) 4 (0.03) 3 (0.025)   11 (0.09) 
Systemic symptoms 3 (0.03) 41 (0.34) 189 (1.56) 5 (0.04) 238 (1.97) 
Anaemia 3 (0.03) 34 (0.28) 185 (1.52) 5 (0.04) 227 (1.87) 
Hypersensitivity reaction   5 (0.04) 3 (0.025)   8 (0.07) 
Skin and appendages 25 (0.21) 48 (0.39) 88 (0.72) 1 (0.01) 162 (1.34) 
Rash itching 16 (0.13) 37 (0.24) 36 (0.29)   82 (0.68) 
Erythema multiforme 
/Exfoliative skin eruptions 
1 (0.01) 7 (0.06) 33 (0.27) 1 (0.01) 42 (0.35) 
Steven Johnson Syndrome   9 (0.07) 12 (0.10)   21 (0.17) 
Exfoliative skin eruptions 1 (0.01)   2 (0.017)   3 (0.025) 
Hyperpigmentation 6 (0.05) 2 (0.02) 5 (0.04)   13 (0.11) 
Central nervous system 3 (0.03) 23 (0.19) 46 (0.38) 5 (0.04) 77 (0.64) 
Nightmares 2 (0.02) 4 (0.03) 12 (0.10) 3 (0.03) 21 (0.17) 
Insomnia   7 (0.06) 10 (0.08) 2 (0.02) 19 (0.16) 
Anxiety/restlessness   3 (0.03) 11 (0.09)  14 (0.12) 
Aggression/irrational talk 1 (0.02) 5 (0.04) 4 (0.03)  10 (0.08) 
Somnolence  3 (0.03) 4 (0.03)  7 (0.06) 
Dizziness    1 (0.01)  1 (0.01) 
Seizures  1 (0.008) 2 (0.02)  3 (0.025) 
Forgetfulness/confusion    3 (0.02)  3 (0.02) 
Hallucination    2 (0.02)  2 (0.02) 
Peripheral nervous system 17 (0.14) 23 (0.19) 19 (0.16)  59 (0.49) 
Peripheral neuropathy 17 (0.14) 23 (0.19) 19 (0.16)  59 (0.49) 
Gastro-intestinal  11 (0.09) 14 (0.12) 25 (0.21)  50 (0.41) 
Nausea and vomiting 3 (0.03) 5 (0.041) 20 (0.17)  28 (0.23) 
Diarrhoea 7 (0.06) 8 (0.07) 3 (0.03)  18 (0.15) 
Abdominal pain 1 (0.01) 1 (0.01) 2 (0.02)  4 (0.03) 
Others* 9 (0.07) 22 (0.18) 24 (0.20)   55 (0.45) 
*jaundice, body swelling, headache, conjunctivitis, oral sores, bone pain, dyspnea, muscle cramp 
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5.6 Factors associated with adverse drug reactions among adults on ART 
Patients’ characteristics that were significantly associated with adverse drug reactions in the 
bivariate analysis included: age, WHO disease stage at treatment initiation, Hepatitis B/ HIV co-
infection, as well as NNRTI and NRTI regimen backbone as shown in Table 5.5. Comparatively, 
the prevalence of ADRs was lower in younger patients compared to older patients (prevalence of 
5%, 7%, and 9% for age groups 15-24, 25-45, and > 45 years respectively; p =0.001), while 
those with more advanced disease (WHO disease stage 4) had lower ADRs compared with those 
at WHO stage 1 to 3. Patients not co-infected with hepatitis B had a significantly higher 
prevalence of ADRs compared to co-infected patients. When the prevalence of ADRs was 
compared according to ARV regimen category; for the NNRTIs, the prevalence of ADRs was 
significantly higher among patients on NVP-based ART compared to those on EFV, and triple 
nucleoside backbones. With respect to NRTI regimen backbone, the prevalence was highest in 
patients on d4T-based regimens, followed by ABC, and least in patients on TDF-based regimens. 
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Table 5.5: Bivariate analysis of association between patients and regimen 
characteristics with the occurrence of adverse drug reactions 
Characteristics Subgroup Number without 
ADR (Row %) 
Number with 
ADR (Row %) 
P 
value* 
Sex Female 7540 (92.52)  610 (7.48)  0.580 
  Male 3657 (92.23)  308 (7.77)   
Age, years 15-24 672 (94.51)  39 (5.49)  0.001 
  25-45 8751 (92.65)  694 (7.35)   
  >45 1730 (90.53)  181 (9.47)   
WHO disease Class 1 or 2 6908 (91.70)  623 (8.31)  0.006 
  3 or 4 3538 (93.20)  258 (6.82)   
CD4 cell count, cells/mm3 ≤100 3907 (92.15)  333 (7.85)  0.503 
  101-200 3638 (92.78)  283 (7.22)   
  200-350 2665 (92.28)  223 (7.72)   
  >350 895 (93.33)  64 (6.67)   
HIV viral load ≤10,000 3006 (93.18)  220 (6.82)  0.093 
  10,001-100,000 4315 (92.52)  349 (7.48)   
  >100,000 3824 (91.83)  340 (8.17)   
Tuberculosis positive No 1101 (79.32)  287 (20.68)  0.696 
  Yes 459 (80.10)  114 (19.9)   
Hepatitis B virus positive No 7702 (91.63)  704 (8.37)  <0.001 
  Yes 2082 (94.29)  126 (5.71)   
NNRTI regimen backbone efavirenz 2520 (94.49)  147 (5.51)  <0.001 
  nevirapine 8504 (91.84)  756 (8.16)   
NRTI regimen abacavir 291 (93.57)  20 (6.43)  <0.001 
  zidovudine 5972 (93.9)  388 (6.10)   
  stavudine 760 (67.68)  363 (32.32)   
  didanosine 251 (93.31)  18 (6.69)   
  tenofovir 3923 (96.82)  129 (3.18)   
ART enrolment year 2004-2006 4431 (0.88)  580 (0.12)  <0.001 
 2007-2009 4995 (0.95)  265 (0.05)   
 2010-2012 1589 (0.97)  57 (0.03)   
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase 
inhibitor, *chi-square comparison of proportion. Values in italics show significant association 
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Table 5.6: Multivariate logistic regression risk factor analysis for adverse drug 
reactions 
Predictor variable  Odds ratio 
(OR) 
95% CI of OR P value 
Sex Females versus males 1.16 0.96 - 1.4 0.137 
Age, years Every 1-year increment  1.02 1.01 - 1.03 <0.001 
WHO disease stage 1or 2 versus 3 or 4 1.05 0.88 - 1.24 0.546 
HBV  status Negative 1.30 1.05 - 1.61 0.015 
NNRT backbone NVP versus EFV 0.78 0.6 - 1.02 0.069 
NRTI backbone abacavir 2.11 1.23 - 3.61 0.007 
 zidovudine 2.22 1.74 - 2.84 <0.001 
 stavudine 15.90 11.97 - 21.11 <0.001 
 didanosine 2.13 1.25 - 3.63 0.006 
 tenofovir Reference   
Year of ART initiation 2004-2006 1.56 1.08 - 2.25 0.018 
 2007-2009 1.26 0.87 - 1.82 0.220 
 2010-2012 Reference   
CI, confidence interval; HBV, hepatitis B virus; NNRTI, non-nucleoside reverse transcriptase 
inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; EFV, efavirenz; 
Values in italics show significant association 
 
The result of the multivariable analysis shown in Table 5.6 identified the following as 
independent predictors of ADRs: age, hepatitis B status, NRTI backbone, and year of ART 
enrolment. The likelihood of experiencing an ADR increased by 2% for every one-year 
increment in age. Hepatitis B co-infection was protective of ADRs; study subjects who were 
hepatitis B negative had 30% greater likelihood of an ADR compared to hepatitis B/HIV co-
infected patients. Considering the NRTI backbone, compared those with a regimen containing 
tenofovir, the odds of an ADR was doubled in patients on abacavir-, stavudine-, and didanosine 
containing ARV regimen respectively. Additionally, the likelihood of an ADR was increased 16 
times among those treated with stavudine-containing regimen compared to tenofovir. 
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Furthermore, there was 56% higher likelihood of experiencing an ADR among those initiated on 
ART in the period 2004 to 2006 compared to the those who commenced treatment between 2010 
and 2012. 
 
5.7 Prevalence of virologic failure among patients on ART at Jos University Teaching 
Hospital 
Figure 5.4 depicts the prevalence of virologic failure at the different time points of ART. The 
proportion of patients with virologic failure (36% at 24 weeks) dropped slightly to 29% at 48 
weeks and then increased to 34% at 72 weeks of ART.  
 
 
Figure 5.4: Percent prevalence of virologic failure at different time point among patients 
on first-line antiretroviral therapy at Jos University Teaching Hospital 2004 – 2012  
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5.8 Factors associated with virologic failure 
Table 5.7: Association of participants demographic, clinical, and regimen 
characteristics with virologic failure  
 Characteristics Sub-group Number (%) of 
patients with 
early (24 weeks) 
virologic failure 
P value Number (%) of 
patients with 
late (72 weeks) 
virologic failure  
P value 
 
Sex Female 2516 (31.02) 0.001 1768 (32.86) 0.093 
 Male 1336 (33.89)  902 (34.76)  
Age, years 15-24 224 (31.64) 0.734 181 (39.61) 0.008 
 25-45 3021 (32.14)  2071 (33.35)  
 >45 593 (31.24)  405 (31.71)  
WHO disease 
stage 
1 975 (24.71) <0.001 791 (29.88) <0.001 
2 1119 (31.5)  826 (33.05)  
 3 1318 (42.89)  792 (38.06)  
 4 254 (35.93)  145 (34.04)  
CD4 cell count 
cells/mm3 
≤100 1610 (37.97) <0.001 1103 (38.91) <0.001 
101-200 1300 (33.15)  824 (28.97)  
 201-350 767 (26.56)  587 (31.39)  
 >350 159 (16.58)  151 (38.42)  
HIV viral load 
copies/ml 
≤10,000 814 (25.23) <0.001 634 (31.31) 0.001 
10,001-100,000 1461 (31.33)  1015 (32.64)  
 >100,000 1577 (37.87)  1021 (35.95)  
Hepatitis B status Negative 2780 (33.23)  0.098 1877 (32.94) 0.605 
 Positive 691 (31.38)  469 (33.67)  
 Yes 243 (42.41)  138 (31.65)  
Tuberculosis No 401 (28.95) <0.001 319 (30.12) 0.561 
Baseline regimen 
backbone 
efavirenz 902 (34.1) 0.001 543 (33.5) <0.001 
Triple NRTI 75 (39.9)  65 (52)  
 nevirapine 2875 (31.2)  2062 (33.1)  
Baseline NRTI abacavir 124 (39.87) <0.001 72 (30.9) <0.001 
 zidovudine 1879 (29.7)  1379 (31.7)  
 stavudine 317 (28.3)  244 (30.1)  
 didanosine 108 (40.2)  69 (36.3)  
 tenofovir 1424 (35.4)  906 (37.9)  
ART start year 2004-2006 1692 (33.6) <0.001 1162 (30.3) <0.001 
 2007-2009 1811 (33.6)  1285 (34.9)  
 2010-2012 346 (21.5)  221 (47.9)  
Adherence† <95% 715 (43.2) <0.001 473 (45.7) <0.001 
  ≥95% 3137 (30.2)   2197 (31.7)   
NRTI, nucleoside reverse transcriptase inhibitor; †average adherence at 24, and 72 weeks were 
included in the analysis of virologic outcome at 24, and 72 weeks respectively; the comparison 
was by chi-square analysis; Values in italics show significant association 
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Table 5.7 summarizes the association between baseline and time-updated patients’ and regimen 
characteristics, and virologic failure.  Early virologic failure was more prevalent in males than 
females (34% versus 31%; p = 0.001), while late virologic failure was more common in the 
younger patients (40%, 33%, and 32%, for age groups 15-24, 25-45, and >45 years respectively, 
p = 0.008). There was a trend toward higher early and late virological failure rates with more 
advanced WHO disease stage at treatment initiation. Additionally, study subjects who initiated 
treatment at higher viral load thresholds had significantly higher early and late virologic failure 
rates. The difference was more pronounced at 24 weeks of treatment; 25% compared to 38%, for 
those with baseline viral load of ≤10,000 compared >100,000 copies/ml respectively. For 
patients with available TB results at baseline, a significantly higher proportion of patients co-
infected with tuberculosis had virologic failure at 24 weeks of therapy compared to non-co-
infected subjects. This difference was not significant at 72 weeks of therapy. A significantly 
higher proportion of study patients who initiated treatment with an ARV regimen of triple NRTI 
had a virologic failure at 24, and 72 weeks of therapy compared to those who commenced 
treatment with EFV- or NVP-based regimen. Considering the NRTI backbone, virologic failure 
rate at 24 weeks was highest among patients who initiated treated with didanosine-based 
regimen, followed by abacavir, tenofovir, zidovudine, and stavudine respectively. However, at 
72 weeks of therapy, patients who initiated ART with tenofovir-containing regimen had the 
highest virologic failure rate of 38%, followed by didanosine (36%), zidovudine (32%), abacavir 
(31%), and stavudine (30%) respectively. Early and late virologic failure was significantly more 
prevalent among those with average percentage adherence to on-time ARV refill schedules of 
<95% compared to those with ≥95% adherence. 
http://etd.uwc.ac.za
51 
 
5.9 Association between adverse drug reaction and virologic failure 
Table 5.8 summarizes the result of comparison of the percentage of virologic failure between 
patients who experienced and those who did not experience an ADR.   
 
Table 5.8: Comparison of virologic failure among study participants who experienced 
an ADR and those who did not experience an ADR  
 Type of ADR  Outcome Number  (%) of 
patients with 
early (24 weeks) 
virologic failure 
 P value Number  (%) of 
patients with late 
(72 weeks) 
virologic failure 
 P value 
Any ADR No 2647 (36.31) 0.297 2436 (33.42) 0.686 
  Yes 235 (34.31)   234 (34.16)   
Grade 3 or 4 
ADR 
No 114 (29.08) 0.223 101 (32.69) 0.462 
  Yes 171 (32.88)   134 (35.36)   
Anaemia No 3765 (31.83) 0.03 2599 (33.22) <0.001 
  Yes 87 (38.84)   71 (46.71)   
CNS disorder No 3739 (31.8) 0.326 2574 (33.10) 0.048 
  Yes 38 (36.2)   31 (44.3)   
Lipodystrophy 
syndrome 
No 3779 (32.18) <0.001 2601 (33.76) <0.001 
  Yes 73 (23.47)   69 (25.46)   
Peripheral 
neuropathy 
No 3835 (31.97) 0.725 2664 (33.61) <0.001 
  Yes 17 (29.82)   6 (12.5)   
Skin disorders No 3814 (31.96) 0.851 2641 (33.44) 0.431 
  Yes 38 (31.15)   29 (37.66)   
ART, antiretroviral therapy; CNS, central nervous system, numbers in parenthesis represent 
percentages. The comparison was by chi-square test. Values in italics show significant 
association 
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5.10 Assessment of predictors of virologic failure 
A multivariate logistic regression model evaluated independent predictors of early (24 weeks) 
and late (72 weeks) virologic failure. Variables that were significantly associated with virologic 
failure to a p =0.05 in the bivariate analysis (Table 5.7 and Table 5.8) were included as 
covariates in the multivariable model to adjust for the effect of confounders on virologic failure. 
Sex and age were included in the model to account for any residual confounder based on the 
apriori knowledge of their association with ADRs (Cescon et al., 2013; Chen et al., 2017). The 
result of the multivariate risk factor analysis is presented in Table 5.9 
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Table 5.9: Multivariate risk factor analysis for virologic failure at 24 and 72 weeks of 
antiretroviral therapy 
 Characteristics Early virologic failure Late virologic failure 
  aOR (95% CI) P value aOR (95% CI) P value 
Males 1.07 (0.96 - 1.19) 0.253 1.18 (1.03 - 1.36) 0.021 
Age, one-year increment 1 (0.99 - 1) 0.501 0.99 (0.99 - 1) 0.083 
WHO disease stage  
(3 or 4 versus 1 or 2) 
1.74 (1.59 - 1.9) <0.001 1.11 (0.98 - 1.24) 0.091 
CD4 cell count, cells/mm3 
(≤100 versus >100) 
1.27 (1.16 – 1.38) <0.001 1.37 (1.23 – 1.53) <0.001 
Viral load (>10,000 versus 
≤10,000) 
1.42 (1.28 - 1.56) <0.001 1.09 (0.97 - 1.24) 0.164 
NVP versus EFV 1.12 (0.99 - 1.28) 0.071 1.39 (1.17 - 1.65) <0.001 
ABC versus TDF 1.2 (0.93 - 1.54) 0.162 0.79 (0.57 - 1.11) 0.173 
AZT versus TDF 0.78 (0.71 - 0.85) <0.001 0.77 (0.68 - 0.87) <0.001 
D4t versus TDF 0.66 (0.55 - 0.79) <0.001 0.88 (0.7 - 1.11) 0.281 
ddi versus TDF 1.08 (0.83 - 1.41) 0.564 1.22 (0.87 - 1.71) 0.264 
Year of ART initiation       
2007-2009 versus 2004-2006 0.91 (0.83 - 1.01) 0.073 1.25 (1.1 - 1.42) <0.001 
2010-2012 versus 2004-2006 0.52 (0.45 - 0.61) <0.001 1.93 (1.51 - 2.46) <0.001 
Adherence  
( <95% versus ≥95%)* 
1.82 (1.63 - 2.04) <0.001 1.74 (1.47 - 2.06) <0.001 
Anaemia 1.34 (1 - 1.8) 0.048 1.76 (1.22 - 2.55) <0.001 
lipodystrophy 0.81 (0.6 - 1.1) 0.183 0.85 (0.61 - 1.18) 0.332 
CNS disturbance -  1.19 (0.68 – 2.05) 0.543 
peripheral neuropathy -  0.42 (0.18 - 1.02) 0.061 
ART, antiretroviral therapy; aOR, adjusted odds ratio; CI, confidence interval; NNRTI, non-
nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; 
HBV, hepatitis B virus; CNS, central nervous system, *average adherence at 24, and 72 weeks 
were included in analysis of virologic outcome at 24, and 72 weeks respectively. Values in italics 
show significant association  
 
. 
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CHAPTER 6 
       DISCUSSION 
6.1 Introduction 
This chapter presents a detailed discussion of the results presented in Chapter 5. The discussion 
highlights key findings of the study with reference to the study objectives. In addition, findings 
of the study were compared with reports published in the literature. An initial brief discussion of 
the demographic and clinical data as well as regimen characteristics is presented. The rest of the 
chapter focuses on adverse drug reactions identified and recorded among patients on ART, 
identified risk factors for ADRs, and the prevalence and risk factors for virologic failure; with 
emphasis on the association between ADRs and virologic failure. 
6.2 Participants characteristics 
The study findings showed that more women (67%) than men were living with HIV; and as such 
more women were accessing antiretroviral viral therapy at the study site. This finding 
collaborates other Nigerian reports which suggest a feminization of the HIV epidemic (Awofala 
& Ogundele, 2015; National Agency for the Control of AIDS (NACA), 2015). Young adults in 
the productive age of 25 to 45 years (78%) were those mostly infected with HIV and accessing 
ART. This finding is consistent with a 2015 report reflecting this age group as the most at risk of 
HIV infection (National Agency for the Control of AIDS (NACA), 2015).  
 
In terms of clinical characteristics, this study revealed that late presentation for treatment was 
common as more than one-third of the participants had severe immune-suppression at treatment 
initiation (CD4+ ≤100 cells/mm3), which meets the European Consensus definition of late 
presentation (UK Collaborative HIV Cohort (UK CHIC) Steering Committee et al., 2010). Other 
Nigerian and African studies also reported late presentation for treatment as common among 
HIV infected patients (Agaba et al., 2014; Daniyam et al., 2011; Mojumdar, Vajpayee, Chauhan, 
& Mendiratta, 2010). Strategies for early detection and integration into care of HIV infected 
persons are needed in the studied setting as late presentation for treatment is a risk factor for 
early mortality in HIV infected patients (Dalhatu et al., 2016). 
On the issue of regimens for ART, the number of different regimens rose sharply from five in 
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2005 to twelve in 2006, before they were streamlined to four in 2008. The sharp rise in the 
number of regimens used in managing HIV coincided with the period of increased external 
funding, mainly from three global health initiatives (GHIs) – the US President’s Emergency Plan 
for AIDS Relief, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the World Bank 
Multi-Country HIV/AIDS Program (Chima & Homedes, 2015). However, using several regimen 
options in one programme to manage HIV infection was not sustainable in the studied setting as 
shown by the sharp decline in the number of available regimen option to four in 2008.  
6.3 Incidence of adverse drug reactions 
This study observed a lower incidence rate of ART-related ADRs (20.4 per 1000 py) compared 
to that reported in earlier African studies: Nigeria (46 per 1000 py) (Eluwa et al., 2012), Ethiopia 
(90 per 1000 py) (Gudina et al., 2017), and Uganda (45 per 1000 py) (Forna et al., 2007). The 
observed differences in the rate of ADRs between the cited studies and the findings of the current 
study could be attributed to several factors: the different pharmacovigilance practices in the 
different settings, the number of patients involved in the studies, the duration of follow-up, and 
individual participant differences in responding to the drugs. Furthermore, severe ADRs had the 
highest prevalence in the current study (Figure 4.5), suggesting a possibility of under-reporting 
or overlooking mild events– further studies are needed to verify this assumption.  
 
Consistent with findings of previous studies (Abah, Akanbi, et al., 2015; Cespedes & Aberg, 
2006; Eluwa et al., 2012; Gudina et al., 2017), this study identified the first year of ART as the 
period of greatest risk for ART-related ADRs [crude incident rate ratio, 2.87; 95% CI: 2.53-
3.24)]. The findings of this study and that of similar studies highlight the importance of close 
monitoring of patients on ART during the first year of treatment to identify and promptly 
manage ADRs when they occur. This will help in mitigating negative consequences of ART-
related ADRs on treatment success. 
 
Type of adverse drug reactions 
The most common ADRs reported in this study were fat distribution abnormalities 
(lipodystrophy; 2.6%), anaemia (1.9%), skin rash/itching (0.7%), and peripheral neuropathy 
(0.5%). The most prevalent ADRs reported by other Nigeria studies were those with early onsets 
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such as skin rash (Kenneth Anene Agu et al., 2014; Eluwa et al., 2012) and anaemia (Ogwuche 
et al., 2014; Reginald et al., 2012). The high rate of fat distribution abnormality reported in this 
study was not captured in earlier Nigerian studies probably due to their short follow up period. 
Although this study did not evaluate the risk factors for specific ADRs, the high prevalence of 
lipodystrophy could be attributed to the stavudine era which is documented in the literature 
(Baril et al., 2005; Joly et al., 2002; Schwenk et al., 2000).  Anaemia, on the other hand, could be 
connected to the high use of zidovudine in the study setting. The association of zidovudine with 
anaemia has been documented in several Nigerian studies (Awodele et al., 2016; Ogwuche et al., 
2014; Oreagba et al., 2014). Consistent to the findings of this study, data from a recent Nigerian 
study with up to five years follow up reported peripheral neuropathy as the most common ADR 
among adults on ART (Bassi et al., 2017). Peripheral neuropathy is a late-onset ADR with a 
reported prevalence in developed countries of about 10% to 21% in persons exposed to stavudine 
(Van-Oosterhout et al., 2005). 
6.4 Factors associated with ADRs 
Age: The prevalence of ADRs was lower in younger patients compared to older patients. After 
adjusting for other confounding variables, we found that the risk of ADRs increased for every 1-
year age increment. Consistent with the study finding, increased risk of ART-related ADRs with 
advancing age had been reported in other African studies (Masenyetse, Manda, & Mwambi, 
2015; Schwenk et al., 2000). 
 
Disease stage: The prevalence of ADRs was found to be higher in patients who initiated ART at 
an early HIV disease stage (WHO clinical stage 1 or 2 compared to stage 3 or 4). Available 
evidence suggests that patients who initiate treatment at an early HIV disease are at higher risk of 
certain ADRs (Centers for Disease Control and Prevention (CDC), 2001). For instance, greater 
risk of NNRTI-related rash was reported in persons with earlier HIV disease after starting 
therapy (Ananworanich et al., 2005). Another possible explanation for the higher prevalence of 
ADRs in asymptomatic patients observed in this study is the fact the study focused on clinical 
ADRs, hence some clinical adverse drug events may overlap with symptoms of HIV/AIDS in 
symptomatic patients (WHO stage 3 or 4) and might be missed, potentially resulting in under-
reporting of ADRs in symptomatic patients. However, HIV disease stage was not predictive of 
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ADRs in the multivariate analysis. This finding is consistent with findings of a multicentre 
randomized controlled study, which found that commencing treatment in early asymptomatic 
HIV infection was not associated with higher risk of adverse drug events (The INSIGHT START 
Study Group, 2015).  
 
Association between regimen characteristics with ADRs   
The association of the type of ARV regimen with the prevalence of ADRs was studied providing 
useful information for the management of antiretroviral therapy.  
 
NNRTIs:  The prevalence of ADRs was higher among patients on nevirapine-based ART 
compared to efavirenz-based ART (8.2% compared to 5.5%; p <0.001). This finding is in line 
with results of a systematic review which demonstrated a greater likelihood of ADRs among 
patients on nevirapine-based ART compared to efavirenz; specifically, with regards to severe 
hepatotoxicity, and severe hypersensitivity reactions (Shubber et al., 2013). However, the review 
found that compared to nevirapine, patients receiving efavirenz were more likely to experience 
severe central nervous system events (Shubber et al., 2013). After adjusting for other 
confounding risk factors in the current study, the risk of ADRs was not significantly different 
between the two drugs, which synchronizes a previous study report that suggested that the short- 
and long-term toxicity and withdrawal rates of the two drugs were comparable (Manfredi, Calza, 
& Chiodo, 2004). 
 
NRTIs: When the NRTIs were compared, as expected, the use of stavudine (32.2%) and 
didanosine (6,9%) were associated with significant risk of ADRs compared to tenofovir (3.3%). 
However, these drugs (stavudine and didanosine) are no longer recommended for first-line 
therapy because of their greater potential for toxicity (World Health Organization (WHO), 2013), 
and their use has been discontinued at the study site. Comparatively, the odds of ADRs was 
doubled among patients exposed to AZT compared to TDF. This result is in line with findings in 
the literature (Gallant et al., 2006; Mudzviti et al., 2015). 
 
Year of ART initiation: We found an almost double likelihood of ADRs among those who 
initiated treatment in the period 2004-2006 compared to those initiated on treatment between 
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2010-2012. Some peculiarities of these treatment periods which might have accounted for the 
observed differences in ADRs included the following: stavudine and didanosine are drugs 
associated with significant risk of ADRs - these were used mostly in the period 2004 – 2006, 
whereas, they were not used in the period 2010 – 2012, as their use had been discontinued based 
on treatment guidelines recommendation (Federal Ministry of Health (FMoH) Nigeria, 2010); 
and the availability of multiple regimen options between 2004 and 2006 compared to between 
2010 and 2012. A higher number of regimen options have been reported to correlate with a high 
rate of regimen modifications (Abah, Darin, et al., 2015), which is associated with increased risk 
of adverse treatment effects (Korsnes, Goodwin, Murray, & Candrilli, 2016). Other possible 
reasons for the observed difference in the prevalence of ADRs related to the calendar years of 
ART initiation are not very apparent and deserve further investigation. 
6.5 Prevalence of virologic failure 
The virologic failure rates in the current study (36% at 6 months and 34% at 18 months) were 
higher than rates reported in Ugandan (20% at 12 months) (Kityo et al., 2014), and South Africa 
(10% at 16 months) (Fox et al., 2012; Sanne et al., 2009). However, the virologic failure rate 
observed in this study was close to estimates of virologic failure rates reported in a systematic 
review and meta-analysis of African studies which put the proportion of patients with 
undetectable viral load at above 64% (35% failure rate) for all time points (Hammond & Harry, 
2008). Another more recent review and meta-analysis of studies from low and middle income 
countries put the number patients with viral suppression after 6 and 48 months on ART at 74.7% 
(95% CI, 72.2–77.2) and 61.8% (95% CI, 44.0–79.7) respectively, which does not differ 
significantly from the result of the current study. This study highlights the need to adopt more 
practical and effective strategies to achieve a higher virologic success rate of 90% in line with 
the United Nations 90-90-90 target (UNAIDS, 2017). 
6.6 Factors associated with virologic failure 
Factors predictive of virologic failure in the current study include the following: 
 
Male gender: The results showed that late virologic failure was higher in males compared to 
females (adjusted odds ratio; 1.18 95% CI:1.03 - 1.36). In contrast to the findings of this study, 
higher virologic failure rates have been reported in females compared to males in other studies; 
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in a Chinese study the adjusted relative risk of virologic failure was 1.02, 95% CI: 1.01 to 1.03 
for females compared to males and (Chen et al., 2017), while a Canadian study reported that 
women were significantly less likely to achieve virologic suppression compared to men (adjusted 
hazard rate; 0.82, 95% CI=0.72–0.93, p=0.002) (Cescon et al., 2013). The inconsistencies in 
gender-related HIV treatment outcomes may be setting specific, and underlying factors in each 
setting need further investigations. 
 
Disease stage: Consistent with results of previous studies (Egger et al., 2002; Law et al., 2015; 
McMahon et al., 2013; Meloni et al., 2016; Scarsi et al., 2015) initiation of ART at more 
advanced HIV disease stage such as WHO disease stage 3 or 4 compared to stage 1 or 2 (OR, 
1.74; 95% CI: 1.59 - 1.9) or severe immunosuppression (pre-treatment CD4+ cell count of ≤100 
compared to >100 cells/mm3) (OR, 1.27; 95% CI: 1.16 – 1.38) increased the likelihood of early 
virologic failure. The implication of this evidence is that late presentation for treatment, which 
was a prominent finding in this study, could be a contributory factor to the poor virologic success 
rate observed in this study. Strategies that support early detection of HIV infection and 
engagement into care are needed in the studied setting to improve treatment outcomes in patients 
on ART. 
 
NNRTI: This study found a higher likelihood of late virologic failure in patients on nevirapine-
based ART compared to efavirenz (OR, 1.39; 95% CI: 1.17 - 1.65). In agreement with findings 
of the current study, the lower hazard of treatment failure among patients on efavirenz- 
compared to nevirapine-based regimens (hazard ratio, 0.66; 95% CI: 0.49-0.88]) had been 
reported in an Ethiopian study (Kedir, Gemeda, & Suleman, 2015). However, evidence regarding 
the superiority of efavirenz compared to nevirapine with regards to virologic suppression rate 
from systematic reviews and meta-analysis are mixed. One systematic review and meta-analysis 
that included 10 trials with 2438 participants suggested that there may be little or no difference 
between efavirenz and nevirapine in virological success rate (Mbuagbaw, Irlam, Spaulding, 
Rutherford, & Siegfried, 2010), whereas, another review which included 38 studies, comprising 
114,391 patients, reported that patients on efavirenz-based ART were more likely to achieve 
virologic success than those on nevirapine-based ART, though the difference was marginally 
significant, (Pillay, Ford, Shubber, & Ferrand, 2013). From the practice point of view, stable 
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patients on either of the drugs (nevirapine or efavirenz) should not be switched except if there are 
compelling reasons. 
 
NRTI: In contrast to evidence from previous studies (Amoroso et al., 2012; Gallant et al., 2006), 
this study found that the likelihood of early (OR, 0.78; 95% CI: 0.71 - 0.85) and late virologic 
failure (OR, 0.77; 95% CI: 0.68 - 0.87) were lower in patients on zidovudine-based ART 
compared to tenofovir-based ART. The superiority of zidovudine compared to tenofovir with 
regards to viral suppression was reported earlier by a retrospective cohort multicentre Nigerian 
study (Scarsi et al., 2015).  
 
Year of ART initiation: In support of a previous multicentre observational cohort study in 
Nigeria (Meloni et al., 2016), we found a significant association between year of ART initiation 
and the risk of virologic failure, with early calendar years of ART initiation being predictive of 
early virologic failure, but protective of late virologic failure. The reason for variability in the 
virologic outcomes between the different cohort of patients merits further investigation as it may 
provide clues on strategies that can be used to improve virologic success rates in the studied 
setting. 
 
Adherence to drug refill schedules: Adherence to on-time ARV refill schedules was associated 
with higher virologic failure rates; proportion of patients with early and late virologic failure of 
43% versus 30%, and 46% versus 32%, respectively for <95% versus ≥95% adherence 
respectively (Table 5.7). After controlling for other confounding variable, patients who were not 
consistent with their drug pick up schedule were more likely to have virologic failure (OR, 1.82; 
95% CI:1.63 - 2.04 for early virologic failure and OR, 1.74; 95% CI:1.47 - 2.06 for late virologic 
failure). The relationship between sub-optimal adherence to drug refill schedules and increased 
risk of virologic failure has been documented in several published reports (Abah et al., 2014; 
Bisson et al., 2008; El-Khatib et al., 2011). 
 
Adverse drug reactions: When specific ADRs were considered in the current study, we found 
that ART-related anaemia increased the odds of late virologic failure (OR, 1.76; 95% CI:1.22 - 
2.55). Studies comparing the impact of ART-related anaemia are scarce, but a recent study found 
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that ADRs were significantly associated with poor immunological and virological outcomes in 
HIV/AIDS patients (Syed et al., 2016). Additionally, in support of the current study finding 
better survival has been reported among HIV patients on ART with the absence of ADRs (Khan, 
Khan, Sulaiman, & Soo, 2015). The relationship between ADRs and virologic suppression may 
be explained by the fact that ADRs are a risk factor for poor adherence (Bezabhe et al., 2015), 
which is on the causal pathway to virologic failure. This fact is supported by the study by 
Bezabhe et al.  (2015), who reported that patients who experienced a severe ADR were less 
likely (OR 0.4, 95 % CI 0.2–0.9) to be ≥90 % adherent to ART.  
 
6.7 Strengths and limitations of the study 
6.7.1 Strengths of the study 
Strengths of the descriptive design 
Findings presented in this study reflect real-life HIV management practices and patients’ 
experiences with regards to ADRs and viral suppression rates in a resource-limited setting.   
 
Strength of the retrospective cohort design 
The retrospective cohort study design enabled the researcher to examine longitudinal data 
spanning a period of 8 years, making it possible to describe the incidence rate and profile of 
ADRs in the studied population. This enabled the researcher to describe the incidence rate of 
ADRs at the different time points of ART and identified a higher incidence of ADRs during the 
first year of therapy compared to subsequent years.  
 
Another strength of the study was the large sample size utilized and long duration of follow-up. 
The availability of electronic medical records made it possible to examine records of all patients 
that met the inclusion criteria (over 12,000 patients were included). As a result, it was possible to 
describe some rare ADRs and to determine the incidence rate of ADRs in the studied population. 
Additionally, the long period of follow up (over 45,000 person-years of observation) enabled the 
researcher to describe late onset ADRs that were not commonly reported in other studies in 
similar settings. Furthermore, the availability of viral load data enabled the researcher to examine 
the risk of virologic failure in those who experienced an ADR and those who did not. Evidence 
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examining this association is scarce.  The large sample size and length of follow up provided 
statistical strength to reinforce our findings. 
 
6.7.2 Limitations of the study 
Retrospective cohort study design 
Instances of missing data for specific variables were encountered because of the retrospective 
use of data. In addition, data were not collected on certain desirable variables such as non-ARV 
medications, which are important in assessing the risk of ADRs. Consequently, we were not able 
to control for all factors related to ADRs and virologic failure, and there might be residual 
confounding that must be considered in the interpretation of the study results. Furthermore, 
because of the retrospective data use, it was not possible to perform a qualitative causality 
assessment of the clinical adverse events.  
 
There also exists the possibility of selective or under-reporting of ADRs by patients and 
caregivers. The study observed that the prevalence of severe ADRs was higher than other grades 
of ADRs. The tendency to overlook mild reaction by patients is high and might have potentially 
underestimated the true prevalence of ADRs in the studied population. In addition, since the 
study focused on clinical ADRs, some adverse drug events which overlap with symptoms of 
HIV/AIDS may have been missed. Furthermore, the researcher observed a trend toward 
documenting the first ADRs reported by patients. The report of subsequent ADRs was very 
sparse and could not be addressed due to the retrospective nature of the study. 
  
Analytic study design 
The retrospective nature of the study made it difficult to confirm the temporal sequence of ADRs 
and virologic failure. While ADRs could occur at any time point in the course of therapy and 
may be transient or chronic, virologic failure was assessed at fixed intervals. When a temporal 
sequence of exposure and outcome cannot be confirmed analytically, it is difficult to estimate the 
risk of the outcome based on the exposure (Bonita et al., 2006). 
http://etd.uwc.ac.za
63 
 
CHAPTER 7 
 CONCLUSIONS AND RECOMMENDATIONS 
7.1 Conclusions 
Antiretroviral therapy related ADRs were common in the studied population with an incident 
rate of 20 per 1000 py, mostly severe in grade, and occurred more frequently in the first year of 
therapy. The observed ADRs rate was lower than rates reported in other resource-poor settings. 
Virologic failure rate at 24, and 72 weeks was high (above 30%) but comparable to those 
reported in similar settings. 
 
The most prevalent ADRs were fat distribution abnormalities such as lipodystrophy (2.7%), 
anaemia (1.9%), skin rash (0.7%) and peripheral neuropathy (0.5%). Other rare but serious 
ADRs such as Stevenson's Johnsons Syndrome (0.2%) and seizures (0.02%) were also observed 
in the study setting. 
 
A number of risk factors associated with ADRs were identified. ADRs were independently 
predicted by older age; 2% greater likelihood of ADR for every year increment, and the use of 
abacavir or stavudine or didanosine ARV regimen compared to TDF containing regimen.  In 
addition, there was a 56% greater likelihood of ADRs in the 2004 to 2006 patient cohort 
compared to the 2010 to 2012 cohort partly attributed to the higher use of stavudine and 
didanosine in 2004 to 2006.  
 
A higher than expected rate of virologic failure ≥30% was observed at 24, 48, and 72 weeks of 
ART, however, the rates were comparable to rates reported in other resource-limited settings. 
Marginal differences were observed in the predictors of early (24 weeks) and late (72 weeks) 
virologic failure. Early virologic was not associated with gender, but late virologic failure was 
independently predicted by male gender with a 19% greater likelihood in males. The likelihood 
of late virologic failure was 29% higher among patients initiated on nevirapine-based ART 
compared to efavirenz. Zidovudine and stavudine-based ARV regimen were protective of both 
early and late virologic failure compared to tenofovir-based regimens. Pre-treatment clinical 
characteristics that independently predicted early virologic failure included WHO disease stage 
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2, stage 3 and 4, CD4+ cell count <200 cells/mm3, and HIV RNA levels >10,000 copies/mL. Late 
virologic failure was predicted by WHO disease stage 2 and 3, CD4+ cell count ≤100 cells/mm3, 
and HIV RNA >100,000 copies/mL. Other predictors of virologic failure included earlier 
calendar year of ART initiation (2004 to 2009) which was predictive of early virologic failure, 
but protective of late virologic failure, and poor adherence to drug refill schedules (<95%) which 
was associated with higher likelihood of both early and late virologic failure. 
 
Of all the ADRs observed in the study, only anaemia was significantly associated with virologic 
failure; with a 74% increase in the likelihood of late virologic failure, after adjusting for age, sex, 
baseline disease stage and CD4+ cell count, antiretroviral regimen, and year of ART initiation. 
7.2  Recommendations 
Policy and practice: The comparatively low rates of ADRs reported in the studied population 
suggests that ARV medication were generally well tolerated among adults, but it also throws an 
important challenge of possible under-reporting of ART-related ADRs. A careful, intensive, 
aggressive and close follow-up of patients, throughout the duration of ART, is recommended to 
track both early and late onset ADRs and to manage them promptly. In addition, causality 
assessments using the appropriate algorithm should be performed and documented for all 
identified ADRs. 
 
Although the use of more toxic ARV drugs such as stavudine and didanosine has been 
discontinued, the association of anaemia with late virologic failure is disconcerting and brings to 
the fore the need for close monitoring of haemoglobin levels in patients on ART for early 
identification and management of anaemia. 
 
There is also an urgent need to adopt more pragmatic and intensive strategies to drive up the 
proportion of patients with virologic success, which is currently <70%, to the United Nations 
optimal target of 90%. In addition, patients who have failed first-line ART should be urgently 
identified and switched to effective second-line therapies. Maintaining patients on failing 
regimens increases the risk of accumulation of resistant mutations and limits future treatment 
options (Rawizza et al., 2013). 
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Future Research: 
To accurately quantify the magnitude of and risk factors for ADRs in the patient population, a 
longitudinal, prospective observational design is recommended, as this will enable a time to 
event analysis of risk factors. Further studies are also recommended to accurately describe the 
profile of early and late onset ART-related ADRs in the patient population. 
 
The reason why the 2004 to 2009 patients’ cohort had better late virologic outcomes compared to 
the 2010 to 2012 cohort should be further investigated, as this might give insight into effective 
strategies to improve virologic outcomes in the study setting. 
 
Three important research questions, which may be pursued in the future, arose from the present 
study. The questions are: 
1. What is the effect of early and late onset ART-related ADRs on patients’ adherence to 
ART?  
2. What is the effect of early and late onset ART-related ADRs on patients’ health-related 
quality of life? 
3. What are effective strategies required to achieve both early and late viral suppression rate 
of 90% among patients on ART in the study setting? 
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APPENDICES 
APPENDIX 1: Data Extraction Form 
 
Part A: Socio-demographics       
1.      Unique identifier:       
2.      Sex-  Male       
 Female       
       
3.      Marital status-  Single       
  Married       
  Separated       
 Divorced       
 Widow/Widower       
4.      Highest education  No formal 
education 
      
 Primary       
 Secondary       
 Tertiary       
       
5.      Occupation- Unemployed       
 Informal 
employment 
      
 Formal 
employment 
      
Part B: HIV risk characteristics       
6.      Mode of HIV transmission Specify       
Part C: Clinical characteristics       
7.      WHO clinical disease stage at base line 1 2 3 4   
8.      TB co-infection at base line Yes No     
9.      Hepatitis B virus co-infection at baseline Yes No     
http://etd.uwc.ac.za
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– 
10.  Hepatitis C virus co-infection at baseline Yes No     
11.  CD4 cell count (cells/mm3)-  Baseline.        
 6 month       
 12 month       
 24 Month       
 36 month       
 48 month       
12.  HIV RNA levels (Viral load) copies/ml-  Baseline       
 6 month       
 12 month       
 24 Month       
 36 month       
 48 month       
 
Part D: Adverse drug reactions (ADR)       
13.  Experience an ADR-  Yes No    
14.  Date of first ADR (If yes to 13 above)- Date     
15.  Severity of ADR (WHO grade)- 1 2 3 4  
16.  Type of first ADR (clinical description based on ICD-10)    
17.  Other ADRs with dates     
18.  Total number of ADRs     
Part E: Medication characteristics       
19.  Date commenced ART: Date     
20.  First Antiretroviral regimen- names and codes    
21.  Other non-antiretroviral drugs     
Part F: Medication adherence characteristics       
22.  Medication refill adherence at months   6 12 24 36 48 
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APPENDIX II: University of Western Cape (UWC) Research Ethics Committee approval 
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APPENDIX III: Jos University Teaching Hospital letter of ethical clearance  
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APPENDIX IV: Harvard T. H. Chan approval letter for use of secondary data 
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APPENDIX V: APIN Centre Jos University Teaching Hospital approval for use of 
secondary data 
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